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Abstract 
ABSTRACT 
Sophora flavescens is a shrub cultivated widely in northeast Asian countries. 
Radix Sophoroe (also k n o w n as KuShen), stipulated as the dried roots of this 
species, is a natural product used in the traditional herbal preparations in 
China for centuries, being prescribed as a n anti-tumor a n d anti-metastasis 
agent against hepatocellular carcinoma (HCC). In the earlier time, several 
bioactive flavonoids w e r e successfully purified a n d identified from this 
medicinal herb. Herein, the project focuses to delve into the possible 
application(s) of the two constituents - Leachianone A a n d Sophoraflavone 
J - on H C C treatment by in vitro a n d in vivo studies. 
Cell viability assay a n d experiments on cell cycle arrest a n d apoptotic events 
s h o w e d that the c o m p o u n d s exerted their anti-proliferative activities on 
h e p a t o m a cells H e p G 2 a n d R H e p G 2 via the induction of apoptosis, with the 
involvement of both extrinsic (death「eceptor-mediated) as well as intrinsic 
(mitochondrial) pathways. Meanwhile, Leachianone A w a s able to retard 
the growth of tumor in HepG2-bearing n u d e mice, as corroborated by the 
17% - 5 4 % reduction of tumor size w h e n c o m p a r e d to the control group. 
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Most importantly, its administration failed to cause a n y toxicity to the heart 
a n d liver tissues of the hosts. 
The s a m e set of tests w a s also c o n d u c t e d with Sophoraflavone J on H e p G 2 
cells, in which cell death w a s again mediated by apoptosis. In attempt to 
further define the mechanism(s) underlying its actions,〇 comparative 
proteomic a p p r o a c h w a s e m p l o y e d . Spots with differential expression 
patterns identified so far included multiple classes of proteins, for instance 
m e m b r a n e proteins/ antigens, structural proteins, transcriptional factors, 
glycolytic enzymes, heat-shock chaperon proteins (HSP), reactive oxygen 
species (ROS)-related proteins a n d proteosomes, etc. The findings were 
confirmed by Western blot analysis a n d real-time P C R . Preliminary 
experiments for characterization of the roles of these proteins w e r e d o n e as 
well. It w a s hypothesized that Sophoraflavone J brought about cell death 
through generation of oxidative stresses, which subsequently led to 
mitochondrial dysfunction. 
In an overall, w e uncovered that the anti-cancer effects of Leachianone A 
a n d Sophoraflavone J were achieved by apoptosis, d e p e n d e n t of the 
Abstract 
activation of caspases-3, -8 a n d -9. Albeit this, cell cycle arrest did not c o m e 
off throughout the whole treatment process. O n the other h a n d , using 
proteomics for the molecular dissection of mechanisms, w e c a m e u p with 
s o m e novel protein candidates of significance in the understanding the full 
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1.1 Human Liver Cancer 
Liver cancer is defined as an excessive, disorganized cell division of the 
hepatocytes, which finally leads to the formation of a n abnormal clump, 
k n o w n as tumor. Hepatocellular carcinoma ( H C C ) or called h e p a t o m a 
represents the majority of malignant liver cancer, as originated from 
hepatocytes themselves. Cholangiocarcinoma is a discrete type, arising 
from the bile ducts in liver a n d proceeding d o w n towards the gallbladder. 
S o m e other rare kinds of liver cancer include angiosarcomas (from the blood 
vessels in the liver), l y m p h o m a s (from the i m m u n e cells in the liver) a n d 
carcinoids (from hormone-making liver cells). 
LL1 Incidence of Hepatocellular Carcinoma 
H C C is the most c o m m o n primary malignant neoplasm of the liver worldwide, 
occurring as o n e of the top five cancers in overall frequency. The disease 
prevails in parts of Asia a n d Africa; yet appears rife in European countries in 
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recent years. It accounts for about 6 % of all h u m a n cancers annually 
( N o w a k ef al., 2004). In 2003, hepatocarcinoma ranked high u p as the third 











































































































































































































































































































































































































































































































































































































































1.1.2 Causes and Symptoms of Hepatocellular Carcinoma 
So far, certain risk factors h a v e b e e n identified to b e vastly related to the 
d e v e l o p m e n t of H C C , including infection with chronic viral hepatitis, primarily 
types B a n d C; a n d a diseased condition called cirrhosis, as resulted from 
haemochromatosis, a u t o i m m u n e diseases a n d alcoholism, etc ( O m a t a et al., 
2004). In a n early cancer stage, the tumor is often too small to cause any 
signs in patients. As it enlarges to a n a d v a n c e d level, though, a b d o m e n 
swelling, weight loss, fatigue, pain a n d para-neoplastic syndromes are 
confronted. Worse still, spread of cancer gives rise to severe intestinal 
blockage, b o n e pain a n d neurological d a m a g e , etc. 
LL3 Treatment Options for Hepatocellular Carcinoma 
N o w a d a y s , standard treatment m e t h o d s for the H C C patients c o m p r e h e n d 
surgical resection, systemic radiotherapy a n d chemotherapy. Unfortunately, 
only 10% - 2 0 % of patients are suitable for resection (Johnson et al., 2002). 
A n d , the response following the radiotherapy a n d c h e m o t h e r a p y is also not 
satisfactory at present. It is because the efficacy of the drugs used is 
h a m p e r e d by the assortment of adverse side-effects exerted on patients. In 
addition, development of multi-drug resistance (MDR) property by cancer 
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cells poses another problem for successful r e m e d y . For these reasons, it 
c o m e s to a n urgent n e e d to explore a n e w a v e n u e for a n effectual therapy 
against this disease. Currently, natural products with historical medicinal 
application arise to help address the point. 
7. J.4 t^ulW-drug Resistance 
M D R is a generic term for the variety of strategies tumor cells employ to 
e v a d e the cytotoxic actions of anti-cancer drugs (Simon ef a/., 1994). 
Prolonged incubation with a single anti-cancer drug always m a k e the cells 
b e c o m e less sensitive a n d m o r e resistant to a broad spectrum of unrelated 
drugs, a p h e n o m e n o n k n o w n as cross-resistance (Stavrovskaya ef ol., 2000). 
LL4. J Mechonisms of Multi-drug Resistance 
i) Inherent F o r m of Multi-drug Resistance 
Depending on the nature of tumor cells, s o m e possess an ability to 
counteract the effects of drugs before therapy. This kind of M D R usually 
c o m e s in the genetically pre-disposed tumor cells; or appears d u e to the 
special locations of the tumors. For example, tumors in the brain are 
impregnable to numbers of therapeutic agents, owing to the presence of 
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blood-brain barrier (BBB). 
ii) A c q u i r e d F o r m of Multi-drug Resistance 
For other cells, on the contrary, they attain M D R after therapy. There are 
several m e a n s , by which the tumor cells operate to e s c a p e from the 
annihilation by drugs, ranging from the declined drug accumulation in cells to 
the abrogation of the onset a n d execution of apoptosis (Tomida et al., 2002, 
Blagosklonny et al., 2003). 
To start with the defense, M D R cells are basically able to c h a n g e the lipid 
compositions of the plasma m e m b r a n e so as to minimize the diffusion of the 
drug molecules into the cells. O n the other hand, they also simultaneously 
activate the expression of s o m e transporter proteins for p u m p i n g out the toxic 
substances (Crude et al., 2002). Until n o w , different superfamilies of proteins 
are k n o w n to b e frequently involved in drug efflux: P-glycoprotein (Pgp), 
multi-drug resistance protein (MRP) a n d breast cancer resistance protein 
(BCRP or M X R ) (Arced et a/., 2000, Leonard ef a/., 2003) (Fig. 1.1.4.1.1). 
Alternatively, cells s o m e h o w stimulate the detoxification enzymes, such as 
glutathione peroxidase (GPx), glutathione S-transferase (GST), a n d 
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superoxide dismutase (SOD), which then facilitate the cancellation of the 
destructive behaviors e v o k e d by the drugs (Lee ef a/., 1996, 丫en et a/., 1998, 
G o u a z e etal； 2001). 
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Figure 1.1.4.1.1. Schematic structure of P-glycoprotein and some examples of its 
substrates. (Adapted from Sorrentino etal., 2002). 
P-glycoprotein (P-gp) is a 170 kDa plasma m e m b r a n e protein e n c o d e d by the M D R 1 
g e n e on the c h r o m o s o m e 7 in h u m a n . It is m e m b e r of the ATP-Binding Cassette 
(ABC) transporters; it possesses 2 homologous and symmetrical halves, each 
containing an ATP-binding domain and 6 trans-membrane domains separated by a 
flexible linker polypeptide. The protein thus forms a negatively charged 
hydrophobic pore of diameter 5 n m . It is proposed that cationic lipophilic substrates 
(including s o m e anti-cancer drugs) are p u m p e d out to the extra-cellular space at 
the expense of ATP. Hence, it reduces the quantity and activity of the anti-cancer 
drugs inside the tumor cells. 
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To secure against cell death, tumor cells deregulate multiple targets in the 
apoptotic pathways, particularly the tumor-suppressor g e n e p53 a n d the 
anti-apoptotic proteins Bcl-2 a n d BC I -XL (Schott ef 〇l., 1995, Walczak et a/., 
2000, Yu et a/., 2004). For long, p53 wild-type g e n e is believed to b e awfully 
important to both the cell cycle progression a n d the control of apoptosis 
(Lowe et a/., 1993). Defects and/ or mutations of p53 delay cell-cycle arrest; 
a n d abolish the D N A repair process, which otherwise render the cells 
apoptosis. Sometimes, inadequate Bcl-2 a n d BC I -XL protein expressions are 
likely to e n h a n c e tumor cell survival (Chipuk et al., 2002). 
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1.2 Traditional Chinese Medicine 
Since ancient times, plant-based formulations h a v e b e e n availed as remedial 
measures against various aliments (Singh ef a/., 2003). They offer an 
overwhelming variety of metabolites, which display diverse medicinal a n d 
pharmaceutical functions (Gerber ef oL, 2002). Nearly 8 0 % of the 
prescriptions today are filled with drugs with active ingredients extracted or 
derived from plants. For instance, analogues of camptothecin from 
Campfofheca acuminate are c o m m o n l y taken for small-cell lung a n d 
colorectal cancers (Oberlies ef a/., 2001). Indirubin from indigofera tincforia 
OS well as harrringtonine from Cephalofaxus hainanesis o w n other unique 
biological activities effective against myelocytic leukemia diseases (Hoessel 
etal” 1999). 
J.2.7 Sophora flavescens and Radix Sophorae 
Sophora flavescens is distributed extensively in China, J a p a n a n d Korea (Fig. 
1.2.1.1). For m a n y years, the roots of the species are applied in folk medicine 
as an anti-asthmatic, anti-carcinogenic/ metastatic, anti-inflammatory, 
anti-pyretic a n d anti-ulcerative agent (Kong ef a/., 2000). The herb is 
characteristic of a bitter taste a n d a cold nature. Inside the body, it is 
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attributive to heart, s t o m a c h , liver, large intestine a n d urinary bladder 
channels. 
Previous phytochemical studies of Radix Sophoroe h a v e reported the 
isolation of quinolizidine alkaloids, flavonoids a n d triterpenoids (Kim ef a/., 
2004). Of t h e m all, flavonoids are r e n o w n e d for their physiological 
anti-neoplastic activity, being able to bring a b o u t the differentiation a n d / or 
growth inhibition in various malignant c a n c e r cells, such as lung, esophageal, 
colorectal breast a n d prostate cancers as well as osteosarcoma (丫amah〇「a 
et�〇/., 1990, D e N a e y e r ef a/., 2004, Xu et a/., 2005). While, alkaloids are 
powerful in relieving the discomfort e m a n a t e d from c o m m o n cold a n d 




Fig. 1.2.1.1 Photographs taken for the whole plant of Sophora flavescens (A) and 





1.2.2 Flavonoid and its Sub-classification 
Flavonoid (also referred to as bioflavonoid) designates a class of plant 
secondary metabolites based around a phenylbenzopyrone structure (Fig. 
1.2.2.1). It is ubiquitous in nature; over 5,000 flavonoids h a v e b e e n found in 
different fruits, vegetables a n d soy. In a c c o r d a n c e with the chemical 
structures, flavonoids are categorized into six sub-groups: flavanones, 
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Fig. 1.2.2.1 Basic chemical unit of a flavonoid. 
The flavonoid is a polyphenolic c o m p o u n d possessing 15 carbon atoms, with 2 
benzene rings joined together by a liner 3-carbon chain. 
http://www.friedli.eom/herbs/phytochem/flavonoids.html#intro 
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Fig. 1.2.2.2 Chemical structures of different types of flavonoids, flavanone (A), 




1.2.3 Flavonoid and Human Health 
Consumption of flavonoids has b e e n coupled with loads of beneficial effects 
on h u m a n health, like heart a n d vascular protection, treatment of 
m e n o p a u s a l symptoms, etc (Koebnick et al., 2005, Carroll et al., 2006, StangI 
ef a/., 2006, Zaveri et a/., 2006). M o r e recently, epidemiological studies h a v e 
d o c u m e n t e d the biologically active properties of flavonoids against various 
kinds of malignancies (Haghiac ef al., 2005, Schmidt et aL, 2005, Colgate ef 
al., 2006). 
In search of the promising c o m p o u n d s against h e p a t o m a , w e c a m e across 
six bioactive flavonoids enriched in Radix Sophoroe, which w e r e capable of 
arresting cell growth in h u m a n h e p a t o m a cell lines significantly. The present 
study e m p h a s e d on the two constituents called Leachianone A a n d 
Sophoraflavone J (Fig. 1.2.3.1). In regard to the classification s c h e m e , they 
belonged to flavanone a n d flavone sub-groups, respectively. Both of them 
herein shared an identical molecular formulae of C26H30O6, with a molecular 
weight of 438. 
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1.3 Cell Death 
Cell proliferation a n d death are crucial c o m p o n e n t s of both normal 
d e v e l o p m e n t a n d pathogenesis, including cancer (Joaquin ef al., 2001, Pru 
ef al” 2001). In a board sense, cells undergo at least two distinct types of 
cell death; the first o n e is necrosis a n d the other, apoptosis. The former is a 
r a n d o m issue; the latter, however, is strictly controlled a n d regulated. 
1.3.1 Necrosis 
Necrotic cell death is a passive form of degeneration affecting massive cell 
populations. It is ascribed to accidental a n d violent tissue injuries; a n d 
a c c o m p a n i e d by cytoplasm swelling, organelle destruction as well as 
disruption of plasma m e m b r a n e , followed by the release of infra-cellular 
contents. In the end, inflammatory reactions are triggered off. 
J.3.2 Apoptosis 
Yet, apoptosis is considered as a well-organized cell death program, which 
e m b r a c e the initiation, execution a n d termination phases. Unlike necrosis, 
apoptosis takes place in individual cells, as characterized by cell shrinkage, 
m e m b r a n e blebbing, maintenance of organelle integrity, chromatin 
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condensation, D N A fragmentation a n d lastly ordered removal through 
phagocytosis (Wyllie ef a/., 1981, G u p t a et a/., 2001). 
Early in 1970s, apoptosis has b e e n put under the entity of p r o g r a m m e d cell 
death (PCD) (Kerr ef a/., 1972). P C D , in a few words, dictates a s e q u e n c e of 
events of cellular metabolism, which ultimately c o m e off with cell destruction 
(Guimaraes et a/., 2003). Other than apoptosis, a u t o p h a g y is another type 
of P C D (Seglenefa/J992). 
7.3.3 Signaling Pathways in Apoptosis 
Generally, initiation of apoptosis involves two major pathways, the extrinsic 








Fig. 1.3.3.1 Outline of the extrinsic (death receptor-mediated) and intrinsic 
(mitochondrial) pathways. 
h 廿 p://w\A/w.biocarta.conn/images/FeaturedProducts/h_mitochondriapathway.gif 
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1.3.3. J Extrinsic (Death Receofor-mediofedl Pathway 
In the extrinsic p a t h w a y , its activation chiefly relies on the binding of s o m e 
death ligands onto the death receptors (DR) present on the cell surface. 
DRs, in fact, are a sub-group of TNF superfamily carrying a specific 80-amino 
acid long cytoplasmic death d o m a i n (DD), which is essential for the induction 
of apoptotic signal following receptor ligation (Kim ef al., 2006). 
Soon with the agonist b o u n d , DRs start to oligomerize; a n d recruit adaptor 
proteins, such as TNF-related associated death d o m a i n (TRADD) or 
Fas-associating protein with death d o m a i n (FADD), through a homophilic 
interaction b e t w e e n the D D of DR a n d the D D of adaptor proteins (Sartorius 
ef a/., 2001). As such, a death-initiating signaling c o m p l e x (DISC) is formed 
to prompt the proteolytic auto-activation of pro-caspase-8. Downstream of 
caspase-8, apoptosis thus either directly activates the effector caspases, like 
caspase 3, to in turn elicit the final apoptotic execution phase in type I cells 
(e.g. BJAB cells); or cleaves the intact Bid protein to generate truncated Bid, 
which then translocates to the mitochondria a n d induces activation of 




1.3.3.2 Intrinsic {Mitochondria" Pathway 
In the intrinsic p a t h w a y , the primary site of action is mitochondria. During the 
course of apoptosis, cellular stress spurs pro-apoptotic proteins a n d represses 
the anti-apoptotic ones to finish u p with the opening of mitochondrial 
permeability transition pores (MPTP) gated b e t w e e n the outer a n d inner 
mitochondrial m e m b r a n e s (Huang et al., 2000). O n c e o p e n e d , release of 
cytochrome c (cyt c) enables the complexation of cyt c, apoptosis 
protease-activating factor-1 (Apaf-1) a n d pro-caspase-9 for a p o p t o s o m e to 
activate caspase-9. At the s a m e time, the mitochondrial m e m b r a n e 
potential (AWm) is also collapsed. Eventually, caspase c a s c a d e continues; 
a n d drives the cells to die. 
1.3.3.3 Cysteine Asparfic Acid Proteoses 
Cysteine-aspartic acid proteases (caspases) are vital to the execution of 
apoptosis in living systems. To achieve rapid activation, they are 
constitutively expressed in cells as z y m o g e n s (pro-caspases) with very low 
activity. These pro-enzymes consist of a pro-domain, a small subunit a n d a 
large subunit. U p o n stimulation, they g o through proteolytic processings to 
get rid of the inhibitory unit; a n d b e c o m e activated. Active caspase 
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e n z y m e s then assist in different aspects to accomplish the process of cellular 
death, d e p e n d i n g on their functions. Briefly, initiator caspases (e.g. 
caspases-8 a n d -9) work to convert the precursors of effector caspases into 
mature proteases. While, effector caspases (e.g. caspase-3), w h e n 
activated, promote the proteolytic cleavage of protein substrates, say 
inhibitor of caspase-activated D N a s e (ICAD) a n d poly-(ADP-ribose) 
polymerase (PARP); a n d subsequently result in the morphological a n d 
biochemical features in apoptotic cells (Stroh efol., 1998). 
1.4 Research Objective(s) 
The research project herein aims to deploy two dissimilar approaches to 
elucidate the anti-proliferative effect of the two flavonoids extracted from 
Radix Sophorae. For Leachianone A, w e a d o p t sets of apoptotic assays to 
investigate its in vitro a n d in vivo cytotoxic activities on H e p G 2 a n d R H e p G 2 
cells. Concerning Sophoraflavone J, w e focus on the comprehensive 
comparison of the proteomes b e t w e e n the control a n d the treated panels of 
H e p G 2 cells; a n d try to find out s o m e key protein candidates associated with 
the action m e c h a n i s m of the drug. 
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2.1 Materials 
2. LI Cell Lines 
A total of three h u m a n cell lines w e r e e m p l o y e d . T w o of them, namely 
H e p G 2 a n d R H e p G 2 w e r e hepatocarcinoma cells chosen herein for 
anti-tumor activity studies. While, the o n e left, WRL-68, w a s from h u m a n 
normal liver tissues; it w a s taken to evaluate the toxicities of the two 
flavonoids prepared from the herb Sophora flavescens on normal cells. 
All the cell lines w e r e purchased from American Type Culture Collection 
(ATCC), with R H e p G 2 cells exclusive. Cells w e r e cultivated as monolayer 
with Rosewell Park Memorial Institute (RPMI) 1640 m e d i u m or Dulbecco's 
Modified Eagle's M e d i u m (DMEM), supplemented with 10% (v/v) 
heat-inactivated fetal bovine serum (FBS), 100 \xg/rr\\ streptomycin a n d 100 
unit/ml penicillin (PS). The cultures were maintained at 37°C in a humidified 
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atmosphere of 5 % carbon dioxide (CO2). Routine sub-culturing of the cells 
w a s performed twice a w e e k . In e a c h passage, the spent m e d i u m w a s 
discarded; cells w e r e rinsed with phosphate-buffered saline (PBS) o n c e 
before trypsinization. Centrifugation at 1,500 r p m for three minutes w a s 
applied to collect the suspended cells. Then, appropriate aliquots of cell 
suspension w a s resuspended in fresh complete m e d i u m ; a n d cultivated in 
n e w tissue vessels. Cells grown in the exponential growth phase w e r e used 
for all experiments. 
2.J.J.I HeoG2 
H u m a n h e p a t o m a cell line H e p G 2 (ATCC #: HB-8065) w a s first derived from 
the liver tumor, which w a s histologically diagnosed as a well-differentiated 
hepatoblastoma, in a 15-year-old Caucasian adolescent male. The cells 
w e r e adherent ones with epithelial morphology. Cultivation of cells were 
carried out in the complete RPMI 1640 m e d i u m , as supplemented with 10% 
(v/v) FBS (Gibco) a n d 1% (v/v) PS (Gibco). A n d , the cultures were 
maintained at 37^C in a humidified atmosphere of 5 % C O 2 . 
2.1.1.2 RHeoG2 
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R H e p G 2 w a s a multi-drug resistant counterpart of H e p G 2 , as previously 
developed in our laboratory. It w a s achieved by incubating its parental 
cells H e p G 2 with a stepwise increase in the doxorubicin (Dox) concentration 
from 0.1 i^M to 100 ^iM. In the selection process, Dox- sensitive cells w e r e 
r e m o v e d ; a n d the resistant ones w e r e continuously cultivated with a rising 
concentration of Dox. Finally, a pure population of Dox-resistant cells w a s 
obtained. The resistant cells w e r e thereafter kept in the complete RPMI 1640 
m e d i u m , with 1.2 juM D o x a d d e d . The multi-drug resistance property of 
R H e p G 2 cells w a s primarily attributed to the up-regulation of M D R l g e n e a n d 
the over-expression of P-glycoprotein (Pgp), as illustrated respectively in the 
Northern blot study a n d Western blot analysis (Chan ef al., 2000). 
2.1.1.3 WRL-68 
Hepatic epithelial cell line WRL-68 (ATCC #: CL-48) w a s originated from the 
normal liver tissue of a fetus. This cell line basically preserved the 
morphologic structure similar to hepatocytes a n d hepatic primary cultures. 
Cell cultures w e r e supported in the standard D M E M m e d i u m supplemented 
with 10% (v/v) FBS a n d 1% (v/v) PS. 
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2.1.2 Culture Media 
All the m e d i a used were purchased in p o w d e r form; reconstitution w a s d o n e 
following the supplier's instructions. Firstly, contents of e a c h m e d i u m p o u c h 
were dissolved in 1 L of deionized or double distilled water (dd.H20). Then, 
indicated a m o u n t of sodium bicarbonate (NaHCOa) w a s a d d e d (2 g/L for 
RPMI a n d 1.5 g/L for D M E M ) ; a n d the p H w a s adjusted to 7.2 at 25 
Afterwards, the m e d i u m w a s sterilized by filtration through a 0.22 lum cellulose 
m e m b r a n e bottle-top filter. Sterilized m e d i u m w a s thus stored at 4°C until 
use. Lastly, complete m e d i u m w a s prepared by the introduction of 10%(v/v) 
FBS a n d l%(v/v) PS to the sterilized plain m e d i u m . 
2.1.2.1 Rosewell Park Memorial Institutef RPMII J640 Medium 
RPMI 1640 (Gibco), consisting of phenol red, 4 m M L-glutamine a n d 0.5 m M 
HEPES, w a s used to cultivate the two h u m a n liver cancer cell lines, H e p G 2 
a n d R H e p G 2 . In s o m e experiments, phenol red-free RPMI 1640 m e d i u m w a s 
utilized to prevent any interference of phenol red to the assay results. 
2. L2.2 Dulbecco's Modified Eagle's Medium fPMEMI 
D M E M (Gibco), consisting of phenol red, 4 m M L-glutamine a n d 4.5 g/L 
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glucose, w a s used, on the other h a n d , to cultivate the h u m a n normal liver 
cells, WRL-68. 
2.L3 Animals 
Four- to six-week-old inbred m a l e n u d e mice e a c h weighing 20 g to 25 g 
w e r e ordered from the Laboratory Animal Services Centre (LASEC) at the 
Chinese University of H o n g Kong. Procedures involving the care a n d use of 
animals w e r e c o n d u c t e d in a c c o r d a n c e with the guidelines listed in the 
Animals (Control of Experiments) Ordinance. 
2.2 Traditional Chinese Medicines and Conventional Anti-cancer 
Drugs 
Radix Sophoroe (also k n o w n as KuShen), stipulated as the dried roots of the 
herbal species Sophora flavescens (voucher n u m b e r 2004-2531), w a s 
obtained in G u a n g z h o u of mainland China. The identity of the plant w a s 
authenticated from its a p p e a r a n c e , odor a n d s o m e other special in-built 
features by experienced technicians (Mr. H o n P M a n d Mr. L〇u CP) from the 
Institute of Chinese Medicine (ICM), the Chinese University of H o n g Kong. 
Purification by silica gel column chromatography yielded six different 
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bioactive c o m p o u n d s herein (see C h a p t e r 1). These flavonoids h a d b e e n 
mostly e n c o u n t e r e d b y several research groups working o n this herb 
previously. Of t h e m all, L e a c h i a n o n e A a n d the novel constituent, n a m e d 
Sophoraflavone J, w e r e selected for further studies in the project. 
Lyophilized p o w d e r of both Leachianone A a n d Sophoraflavone J w a s 
dissolved in absolute ethanol, filtered a n d then stored at -20°C. Stock 
concentration w a s kept at 690 )LIM (10 mg/ml). For all experiments, the final 
concentrations of the tested c o m p o u n d ( s ) w e r e prepared by diluting the 
stock with c o m p l e t e RPMI or D M E M m e d i u m . 
Cis-platinum(ll) diammeine dichloride (DCPP), or called cisplatin, w a s 
prepared by dissolving in autoclaved PBS to give a stock concentration of 
500 m M . Thereafter, the solution w a s frozen at -20°C for later use. 
Paclitaxel, also k n o w n as taxol, w a s prepared by dissolving in autoclaved PBS 
to give a stock concentration of 50 m M . Thereafter, the solution w a s frozen 
at -20OC for later use. 
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Doxorubicin (Dox) w a s prepared b y dissolving in sterilized PBS for a stock 
concentration of 17.24 m M . The solution w a s aliquoted; a n d stored at -20°C 
until use. Working concentration w a s obtained by diluting the stock solution 
with PBS to 1 m M . 
Staurosporine (STS) w a s prepared by dissolving in sterilized PBS; the stock 
concentration w a s set as 1 m M . The solution w a s kept as small aliquots at 
-20°C until use. Working concentration w a s obtained by diluting the stock 
solution with PBS to 1 |LIM. 
2.3 Antibodies 
Antibody Species Dilution used Supplier 
Primary Antibodies 
anti-apoptosis inducing mouse 
1 : 2000 Santa Cruz Biotechnology 
factor, AIF monoclonal 
rabbit 
anti-bad 1 : 1000 Santa Cruz Biotechnology 
I polyclonal 
mouse 
anti-bax 1:1000 Santa Cruz Biotechnology 
monoclonal 
mouse 
anti-bcl-2 1 : 1000 Santa Cruz Biotechnology 
monoclonal 
mouse 
anti-bcl- XL 1 : 1000 Zymed 
monoclonal 
anti-beta-actin mouse 1 :5000 Sigma 
29 
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monoclonal 
rabbit 
anti-bid 1 : 1000 Santa Cruz Biotechnology 
polyclonal 
m o u s e 
anti-cytochrome c 1 : 1000 Pharmingen 
monoclonal 
anti-enolase goat polyclonal 1 : 1000 Santa Cruz Biotechnology 
anti-glucose regulated goat 
1 : 1000 Santa Cruz Biotechnology 
protein 75, GRP75 monoclonal 
anti-glucose regulated m o u s e 
1 : 1000 Z y m e d 
protein 78, GRP78 monoclonal 
anti-heat shock protein mouse 
1 : 1000 Z y m e d 
70, HSP 70 monoclonal 
anti-inhibitor of caspase rabbit 
1 : 2000 Santa Cruz Biotechnology 
activated DNase, ICAD polyclonal 
anti-poly-(ADP-ribose) rabbit 
1 : 2000 Santa Cruz Biotechnology 
polymerase, PARP polyclonal 
mouse 
anti-procaspase-3 1 :500 Santa Cruz Biotechnology 
monoclonal 
mouse 
anti-procaspase-8 1 : 1000 Calbiochem 
monoclonal 
mouse 
anti-procaspase-9 1 : 1000 Stressgen 
monoclonal 
Secondary Antibodies 
anti-mouse IgG-HRP donkey 1 :2000 Santa Cruz Biotechnology 
anti-goat IgG-HRP donkey 1 :2000 Santa Cruz Biotechnology 
anti-rabbit IgG-HRP donkey 1 :2000 Santa Cruz Biotechnology 
Table 2.1 A list of antibodies employed for Western blot experiment. 
2.4 Chemicals 
I Name and Formula of Chemical |[~Molecular : Source 
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Weight 
Genepath 
lOObp D N A marker — 
Technology 
2-mercaptoethanol (p-ME; C2H6OS) 78.1 Sigma-Aldrich 
3-[(3-cholamidoproplyl)-diiTiethylammonio]-l-
propane (CHAPS; C32H58N2O7S) ‘ 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
414.3 Sigma-Aldrich 
bromide, thiazoyi blue (MTT; Ci8Hi6N5SBr) 
5, 5 ’ � 6 , 6'-tetrachloro-l, 1 ’ � 3 , 3’ Molecular 
652 
-tetraethylbenzimidazolcarbocygnine iodide (JC-1) Probes 
A m e r s h a m 
a-cyano-4-hydroxycinnamic acid (CHCA) — 
Biosciences 
acetic acid ( C H 3 C O O H ) 60.05 Merck 
A m e r s h a m 




(30% solution, mix ratio 37.5:1) 
agarose — USB 
albumin, bovine (BSA) — Sigma-Aldrich 
a m m o n i u m bicarbonate (CH2O3H3N) 79.06 Sigma-Aldrich 
a m m o n i u m persulfate (APS; (NH4)2S2〇8) 228.2 Bio-Rad 
annexin V-FITC --- Trevigen 
apologix carboxy-fluorescein caspase detection kit — Edward-Keller 
aprotinin 6500 Sigma-Aldrich 
benzamidine, hydrochloride hydrate (C7H8N2HCI) 156.61 Sigma-Aldrich 
bicinchoninic acid (BCA) solution — Sigma-Aldrich 
boric acid (H3BO3) 61.83 USB 
bromophenol blue, sodium salt (Ci9H9Br4〇5SNa) 691.9 Sigma-Aldrich 
cis-platinum(ll) diammeine dichloride or cisplatin 
300 Sigma-Aldrich 
(CDDP; Pt(NH3)Cl2) 
chloroform — Sigma-Aldrich 
commassie brilliant blue R-250 (C45H44N507$2Na) 825.99 USB 
copper(ll) sulfate pentahydrate (CuS〇4.5H2〇） 249.68 Sigma-Aldrich 
diethyl pyrocarbonate (DEPC; C6H10O5) 162.1 Sigma-Aldrich 
dithiothreitol (DTT; HSCH2(CH〇H)2CH2SH) 164.24 Sigma-Aldrich 
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digitonin (C22H26N2O4S) 1228 Sigma-Aldrich 
dimethylsulfoxide (DMSO; CH3SOCH3) 78.13 Invitrogen 
doxorubicin (D〇X; C27H29NO1 iHCI) 580.0 Sigma-Aldrich 
A m e r s h a m 
drystrip cover fluid — 
Biosciences 
Dulbecco's Modified Eagle's M e d i u m (DMEM) --- Gibco 
A m e r s h a m 
e n h a n c e d chemiluminescence reagents (ECL) — 
Biosciences 
ethanol (C2H5〇H) 46.07 Merck 
Molecular 
ethidium bromide (EtBr) 394 
Probes 




fetal bovine serum (FBS) … Gibco 
formaldehyde 37% solution or formalin (CH2O) 30.03 Sigma-Aldrich 
glutathione apoptosis detection kit, fluorometric --- Calbiochem 
glycerol (H〇CH2CH(〇H)CH2〇H) 92^ USB 
glycine (H2NCH2CO2H) 75.07 USB 
hydrochloric acid (HCI) 36.45 BDH 
in situ cell death detection kit, fluorescein --- Roche 
iodoaceamide (lAA; C2H41NO) 184.96 Sigma-Aldrich 
isopropanol ((CH3)2CH〇H) — Merck 
leupeptin (C20H38N6〇4) 463 Sigma-Aldrich 
magnesium chloride, hexahydrate (MgCl2.6H2O) 203.30 USB 
methanol (CH3OH) 32.1 Merck 
n-hexane (CH3(CH2)4CH3) 86.18 Lab-Scan 
N, N, N'-tetramethyl-ethylene diamine (TEMED) 116.21 Bio-Rad 
non-fat milk powder — Nestle 
paclitaxel or taxol (C47H51NO14) 853.9 Sigma-Aldrich 
paraformaldehyde 30.03 Sigma-Aldrich 
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phenol-chloroform-isoamyl alcohol 
Invitrogen ---(mix ratio 25:24: 1) 
potassium chloride (KCI) 74.55 Sigma-Aldrich 
potassium phosphate, dibasic anhydrous (K2HP04) 174.18 USB 
potassium phosphate, monobasic anhydrous 
136.09 USB (KH2P04) 
potassium ferricyanide (K3Fe(CN)6) 329.24 Sigma-Aldrich 
propidium iodide (PI) 668.4 Sigma-Aldrich 
proteinase K, 16U/mg protein --- Sigma-Aldrich 
protein rainbow marker (full-range) --- Invitrogen 
ribonuclease A, 1 02U/mg protein (RNase A) --- Sigma-Aldrich 
Rosewell Park Memorial Institute (RPMI) 1640 --- Gibco 
sequencing grade modified trypsin --- Promega 
sheath fluid --- USB 
silica gel --- Merck 
silver nitrate (AgN03) 169.9 Sigma-Aldrich 
sodium acetate (CH3COONa) 82.03 USB 
sodium bicarbonate (NaHC03) 84.01 Sigma-Aldrich 
sodium carbonate (N02C03) 105.99 Sigma-Aldrich 
sodium chloride (NaCl) 58.44 USB 
sodium citrate, trisodium salt 
294.1 Sigma-Aldrich 
HOC(COONa) (CH2COONa)2. 2H20 
sodium dodecyl sulfate (SDS: CH3(CH2) IIS04Na) 288.38 USB 
sodium hydroxide (NaOH) 40.00 Sigma-Aldrich 
sodium phosphate, dibasic heptahydrate 
268.07 USB (Na2HP04. 7H20) 
sodium phosphate, monobasic monohydrate 
137.99 USB (NaH2P04. H2O) 
sodium thiosulphate (N02S203. 5H20) 248.19 U5B 
sodium orthovanadate (Na3V04) 183.9 Sigma-Aldrich 
staurosporine (5T5) 466.5 Calbiochem 
sucrose (CI2H22011) 342.3 Sigma-Aldrich 
trifluoroacetic acid (TFA: CF3COOH) 114.02 5igma-Aldrich 
tris (NH2C(CH20H)3) 121.14 U5B 
_________________________________________________ 33 
Chapter 2 
Materials and Methods 
triton X-100 — USB 
TRIzol reagent --- Invitrogen 
trypan blue solution — Sigma-Aldrich 
trypsin-EDTA — Gibco 
tween 20, polyoxyethylene sorbitan monolaruate --- USB 
urea (NH2CONH2) 60.06 USB 
xylene cyanol FF�(C25H27N2〇6S2Na)� 538.6� Sigma-Aldrich�
Table 2.2 A list of chemicals used, their chemical/ common names, formula, 
formular weights and the sources to obtain. 
2.5 Reagents and Buffers 
Buffers�w e r e� prepared� by� dissolving� chemicals� in�dd.H2〇；�a n d� titrated� to�
suitable�p H�with�either�HCI�or�Na〇H,�unless�otherwise�specified.�
2.5.1 Reagents for Silica Gel Column Chromatography 
Silica gel column�w a s� prepared� by� mixing� every� 1�g� silica�gel�with� 4� ml�
stationary�ph a s e�solvent,�ethyl�acetate.�
2.5.2 Buffers for Common Use 
PBS�w a s� c o m p o s e d� of�2�m M� KH2PO4,�2.7�m M KCL 10 m M� Na2HP〇4�a n d� 137�
m M� NaCI;� its�p H� w a s� titrated� to� 7.4.� Afterwards,�it�w a s� autoclaved� for�
sterilization; a n d stored at 4°C. 
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2.5.3 Reagents for Cell Viability Assay 
MTT solution w a s prepared b y dissolving the M T T p o w d e r in PBS to give a 
concentration of 5 m g / m l . The resulting solution w a s filtered through a filter 
p a p e r to r e m o v e precipitates. At last, M T T solution w a s kept at 4°C for use in 
a later time. 
2.5.4 Reagents and Buffers for Typical Apoptosis Experiments 
2.5.4.1 Cell Cycle Analysis 
PI stain solution w a s prepared by dissolving PI (20 lug/ml), R N a s e A (10 |Lig/ml) 
a n d 1 % (v/v) Triton X-100 in PBS. 
2.5.4.2 Terminal Deoxynucleofidyl Transferose-mediated dilTP Nick End 
Labeling /TUNELI Assay 
Fixation buffer w a s prepared by dissolving 4 % (w/v) paraformaldehyde in PBS. 
Permeabilizatlon buffer w a s prepared by dissolving 0.1% (v/v) Triton X-100 in 
0.1% (w/v) sodium citrate. 
2.5.4.3 DMA Fraamentatioii Detection 
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DNA lysis buffer w a s c o m p o s e d of 100 m M EDTA, 200 m M Tris-HCI (pH8.3) a n d 
1 % S D S . 
Tris-EDTA (TE) buffer w a s c o m p o s e d of 1 m M E D T A a n d 10 m M Tris-HCI (pH7.0). 
Proteinase K w a s dissolved in�dd.H2〇�with�10�m g / m l�as�a�stock�concentration.�
It�w a s�kept�at� until�use.�
Ribonuclease A� w a s� dissolved� in TE buffer with 0.2 m g / m l as a stock 
concentration. Also, it w a s kept at -20oC for later use. 
1 X Tris-Borate-EDTA (TBE) buffer w a s c o m p o s e d of 89 m M boric acid, 2 m M 
E D T A a n d 89 m M Tris-HCI (pH8.0). 
6 X DNA loading dye w a s c o m p o s e d of 4 0 % (w/v) sucrose, 0.25% (w/v) 
b r o m o p h e n o l blue a n d 0.25% (w/v) xylene cyanol FF. 
2.5.5 Reagents and Buffers for Western Blot Study 
4 X resolving gel buffer w a s c o m p o s e d of 1.5 M Tris-base a n d 14 m M SDS. 
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The buffer p H w a s adjusted to 8.8. 
4 X stacking gel buffer w a s c o m p o s e d of 0.5 M Tris-base a n d 14 m M SDS. The 
buffer p H w a s adjusted to 6.8. 
1 X SDS running buffer w a s c o m p o s e d of 250 m M glycine, 25 m M Tris-base 
(pH8.3) a n d 0.1% (w/v) SDS. 
6 X SDS loading dye w a s c o m p o s e d of 300 m M Tris-HCI (pH6.8), 600 m M DTT, 
6 0 % (v/v) glycerol, 1 2 % (w/v) SDS a n d 0.6% (w/v) b r o m o p h e n o l blue. 
1 X electro-blotting buffer (E-blot Buffer) w a s c o m p o s e d of 39 m M glycine, 48 
m M Tris-base, 2 0 % (v/v) methanol a n d 0.0375% (w/v) SDS. Buffer w a s 
calibrated to p H 8.3 for use. Freshly prepared buffer w a s always preferred 
for the experiments. 
Commassie blue staining solution w a s prepared by mixing acetic a d d , 
ethanol a n d� dd.H2〇�in�the� ratio�of� 1:4.5:4.5,�with 0.25% (w/v) c o m m a s s i e 
brilliant blue R-250 a d d e d . 
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De-staining solution� w a s� prepared� by� mixing� acetic� acid,� ethanol� a n d�
dd.H2〇�in�the�ratio�of�1:4.5:4.5.�
1 X PBS-Tween 20 (PBS-T) w a s c o m p o s e d of 2 m M KH2PO4, 2.7 m M K C L 10 m M 
Na2HP〇4,�137�m M� Na C I�a n d 0.002% (v/v) Tween-20. Buffer w a s then titrated 
to p H 7.4 for use. 
Protein standards (2 m g / m l 一�10�mg / m l )�w e r e�prepared�by�dissolving�0.02�g 一 
0.1�g�BSA�in�10�ml�PBS.� The�standards�w e r e�kept�at�-20。C�until�use.�
BCA assay solution�w a s� prepared�with�reagents�A� a n d� B�mixed� in�a�ratio�of�
49:1.� R e a g e n t�A� (bicinchoninic�acid�solution)�w a s� purchased� ready�to�use.�
Re a g e n t�B�w a s�prepared�by�dissolving 4 % (v/v)�CuS〇4.5H2〇�in�dd.H2〇.�
2.5.5. / Whole-cell Protein Extraction 
Cell lysis buffer w a s c o m p o s e d of 4.9 M M g C b , 100 m M N a V O s a n d 10% (v/v) 
Triton X-100. All these c o m p o n e n t s w e r e dissolved in PBS; a n d the buffer p H 
w a s titrated to 7.4. Prior to use, aprotinin (2.1 mg/ml), leupeptin (1.0 m g / m l ) 
a n d P M S F (0.2 m g / m l ) w e r e freshly introduced to the buffer. 
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2.5.5.2 Mitochondrial and Cvfosolic Fraction Protein Ex什action 
Lysis buffer w a s basically c o m p o s e d of 75 m M NaCI, 1 m M� NaH2P〇4,�8� m M�
Na2HP〇4� a n d� 250� m M� sucrose. Various concentrations of digitonin w e r e 
included in the buffer herein for cell lysis - 0.5 m g / m l for cytosolic a n d 5 
m g / m l for mitochondrial protein fractions. All the chemicals w e r e dissolved 
in PBS. Again, the buffer p H w a s titrated to 7.4. Just before use, aprotinin 
(2.1 mg/ml), leupeptin (1.0 m g / m l ) a n d P M S F (0.2 m g / m l ) w e r e freshly 
introduced to the buffer. 
2.5.6 Reagents and Buffers for Mitochondrial Transmembrane 
Potential Depolarization Measurement 
JC-1 dye w a s dissolved in D M S O for a stock concentration of 2.5 m M . The 
d y e solution w a s protected from light; a n d stored at 4°C for later use. 
2.5.7 Reagents and Buffers for in vivo Animal Study 
Saline w a s c o m p o s e d of 0.9% (w/v) NaCI. It w a s kept at�4。C�until�use.�
Pentobarbital�w a s�dissolved�in�PBS�with�a�concentration�of�25�mg / m l .� It�w a s�
protected�from�light;�a n d�kept�at 4°C until use. 
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2.5.8 Reagents and Buffers for Two-Dimensional Gel Electrophoresis 
2.5.8.1 Somole Preparation 
Lysis buffer (LB) w a s c o m p o s e d of 40 m M DTT, 8 M urea a n d 4 % (w/v) C H A P S . 
It w a s then aliquoted; a n d frozen at�-2〇°C. 
2.5.8.2 First Dimension Gel Electrophoresis - Isoelectric Focusing IIEFI 
Rehydration buffer (RB) w a s c o m p o s e d of 8 M urea, 2% (w/v) C H A P S a n d 
0.002% (w/v)�br〇m〇phen〇丨�blue.� The� buffer�w a s� kept�as�small�aliquots� at�
-20°C. U p o n used, 1 % (w/v) DTT a n d 1 % (v/v) IPG buffer w e r e freshly a d d e d 
to the buffer. 
Bradford protein assay reagent w a s prepared with the reagent diluted in 
dd.H2〇，thus�to�h a v e 10% (v/v) as the working concentration. 
2.5.8.3 Second Dimension Gel Electrophoresis - SDS-Polvocrvlamide 
Gel Electrophoresis (SDS-PAGE) 
Equilibration buffer (EB) w a s c o m p o s e d of 75 m M Tris-HCI (pH8.8), 6 M u r e a 
29.3% (v/v) glycerol, 2 % (w/v) SDS a n d 0.002% (w/v) b r o m o p h e n o l blue. 
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Equilibration buffer A w a s prepared with 1 % (w/v) DTT freshly introduced to 
the EB. 
Equilibration buffer B w a s prepared with 2.5% (w/v) lAA freshly introduced to 
the EB. 
Agarose sealing solution w a s prepared by dissolving 0.5% (w/v) agarose a n d 
0.002 (w/v) b r o m o p h e n o l blue in SDS buffer. 
2.5.8.4 Silver Staining 
Fixation solution w a s c o m p o s e d of 10% (v/v) acetic acid a n d 4 0 % (v/v) 
ethanoL 
Sensitizing solution w a s c o m p o s e d of 6.8% (w/v) sodium acetate, 5 % (w/v) 
sodium thiosulphate a n d 3 0 % (v/v) ethanoL 
Silver nitrate solution w a s prepared by dissolving 2.5% (w/v) silver nitrate in 
n a n o pure water. 
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Developing solution w a s c o m p o s e d of 2.5% (w/v) sodium c a r b o n a t e a n d 
0.1% (v/v) 3 7 % formaldehyde. 
Stopping solution w a s prepared by dissolving 1.5% (w/v) E D T A in n a n o pure 
water. 
Storage solution w a s c o m p o s e d of 12% (v/v) acetic acid a n d 4 0 % (v/v) 
ethanol. 
2.5.9 Reagents for Mass Spectrometry Preparation 
2.5.9.丨 Destainina 
Destaining solution�w a s� prepared� by� mixing� 30� m M� potassium� ferricyanide�
with�100�m M� sodium�thiosulphate�in�a�ratio�1:1,�prior�to�use.�
2.5.9.2 Trypsin Digestion 
Gel equilibration solution�w a s�c o m p o s e d� of�200�m M� a m m o n i u m� bicarbonate.�
The�solution�w a s�generally�stored�at 4°C. 
Trypsin enzyme w a s dissolved in 50 m M a m m o n i u m bicarbonate to give a 
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concentration of 40 ng/\i\. The e n z y m e so obtained w a s then frozen at 
-20。C.�
2.5.9.3 Desolfina of Peptide Mixture 
Resuspension solution [0.1% (v/v) TFA] w a s prepared from the serial dilutions 
of 100% TFA to 10%, then to 1%, a n d finally to 0.1% with n a n o pure water. 
Wetting solution [50% (v/v) ACN] w a s prepared by mixing equal volumes of 
100% A C N a n d n a n o pure water. 
Elution solution w a s prepared to h a v e 5 0 % (v/v) A C N a n d 0.1% (v/v) TFA 
present in n a n o pure water. 
CHCA matrix w a s dissolved in a solution containing 5 0 % (v/v) A C N a n d 0.5% 
(v/v) TFA until saturation. 
2.5.10 Reagents and Buffers for Real-Time PCR 
DEPC -H2O w a s prepared with 0.1% (v/v) D E P C dissolved in�dd.H2〇.� The�
resulting�solution�w a s sterilized by autoclave. 
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2.6 M e t h o d s 
2.6. J Isolation of Bioactive Constituents by Silica Gel Column 
Chromatography 
The dried roots of the herb (about 4 kg) w e r e first s o a k e d a n d boiled in 4 L 
absolute ethanol for t w o hours. The s a m p l e w a s then filtered; w h e r e a s the 
residue w a s further extracted under the s a m e condition twice. The filtrates 
collected from three separate extractions w e r e thus c o m b i n e d , 
concentrated a n d partitioned b e t w e e n 1:1 ethyl acetate : water three times 
to give a n ethyl acetate fraction of 1.3 L. This w a s followed by evaporating 
the solution to dryness under a r e d u c e d pressure, so that a s a m p l e weighing 
a b o u t 136 g w a s resulted. 
The crude extract w a s next subjected to silica gel c o l u m n c h r o m a t o g r a p h y 
(20 c m X 8.5 c m ; 8.5 ml/minute), using 1:1 ethyl acetate : h e x a n e as the 
solvent system. The semi-purified Leachianone A- a n d Sophoraflavone 
J-containing fractions w e r e allowed to dry under v a c u u m to confer a yield of 
a b o u t 37.24 g a n d 2.08 g, respectively. The purity of the fractions w a s 
monitored a n d judged by w a y s of the p a p e r chromatography, in which the 
fractioned substance w a s assigned to run alongside the standards on the 
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p a p e r for colour a n d displacement comparison. F e w e r spots d e n o t e d a 
relatively pure chemical fraction. Further purification of the t w o target 
c o m p o n e n t s then c a m e to m a k e use of different strategies. For 
L e a c h i a n o n e A fraction, it w a s applied to another silica gel c o l u m n of smaller 
pore size (24 c m x 5 c m ; 4 ml/minute), with 1:5 ethyl acetate : h e x a n e as the 
solvent system. While, fraction of Sophoraflavone J w a s passed to the 
reversed p h a s e high-performance liquid c h r o m a t o g r a p h y (HPLC), with 1:1 
acetonitrile : water as the solvent system. In the e n d of the process, 469.2 
m g of Leachianone A a n d 56.7 m g of Sophoraflavone J of high purity w e r e 
obtained. 
2.6.2 Cell Viability Assay 
Cells (1 X 104 per well) w e r e s e e d e d in 96-well flat-bottom microplates (Iwaki); 
a n d cultivated in a humidified incubator for adhesion overnight. After that, 
cells w e r e exposed to various concentrations of Leachianone A a n d 
Sophoraflavone J (0 |Lig/ml 一�20�lug/ml);�a n d�continued�for�three�different�time�
durations�(24�h「，48�hr�a n d� 72�hr).� Following�the�incubation,�the�me d i a� wer e�
discarded;�30�jul�of�MTT�solution�w a s� subsequently�a d d e d� to�the�wells.� The�
plate�w a s�thus�allowed�to�stand�at 37°C in the dark for additional three hours. 
Chapter 2 
Materials and Methods 
The MTT-formazan crystals so formed w e r e dissolved in 100 ]i\ D M S O ; a n d the 
a b s o r b a n c e w a s m e a s u r e d specto-photometrically at 540 n m using a n ELISA 
plate reader (Bio-Rad). The cell viability w a s expressed as the optical density 
ratio of the treatment to control (PBS-treated cells) calculated from the 
absorbance values. 
2.6.3 Typical Apoptosis Experiments 
2.6.3. / Cell Cycle Analysis 
Cells (3 X 105 per well) w e r e s e e d e d in 6-well plates (Iwaki); a n d exposed to 
different drug(s) concentrations for 48 hours. They w e r e then harvested, 
w a s h e d a n d fixed with 7 0 % ice-cold ethanol at overnight. Afterwards, 
cells w e r e w a s h e d twice with PBS; a n d incubated in 1 ml PI stain solution 
containing 10 lug/ml RNase A at� 37。C� in� the� dark� for� 30� minutes.�
Fluorescence�signals�emitted�from�the�PI-DNA�comple x�wer e�collected�at FL-2 
channel in a log scale for 10,000 events, using the FACSort flow cytometer 
(Becton Dickinson). Data acquired were analyzed by the WinMDI software 
(version 2.8), d o w n l o a d e d at http://facs.scripps.edu/software.html (Becton 
Dickinson). 
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2.6.3.2 Annexin V-FITC/ PI Sfainina Experiment 
Cells (3 X 105 per well) in 6-well plates (Iwaki) under treatments with different 
concentrations of drug(s) for 48 hours w e r e collected, w a s h e d a n d stained, 
according to the manufacturer's protocol (Trevigen). In brief, the cells w e r e 
w a s h e d twice with 400 ]x\ 1 x binding buffer; a n d then incubated in 100 |LII 
reagent mix containing 1 annexin V-FITC conjugate a n d 10 |il PI in the dark 
for 15 minutes at r o o m temperature. Thereafter, the samples w e r e subjected 
to FACSort flow cytometric m e a s u r e m e n t (Becton Dickinson).� Again,〇�total�
of�10,000�events�we r e�acquired�for�e a c h�sample�given.� Both FL-1 a n d FL-3 
channels, set at log scales, w e r e selected for the detection of signals from 
annexin V-FITC a n d PI, respectively. Result interpretation w a s d o n e with a 
contour plot by the W i n M D I software (Becton Dickinson). 
2.6.3.3 Terminal Deoxynucleofidyl Tronsferose-mediofed dilTP Nick End 
Labeling (TUNEU Assay 
The TUNEL assay for in situ detection of apoptosis w a s performed with the in 
situ Cell Death Detection Kit, Fluorescein (Roche). After 48-hour drug(s) 
treatment, cells (1 x lO) w e r e first put in the fixation buffer at 25°C for o n e 
hour. Fixed cells were then transferred to the permeabilization buffer; a n d 
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incubated with the fluorescein-conjugated dUTP in a terminal 
deoxynucleotidyl transferase-catalyzed reaction at� 37。C� in� the� dark� for�
another�hour.� Finally,�the�samples�wer e�w a s h e d� twice;�a n d� resupended�in�
500 ]x\ PBS ready for subsequent FACSort flow cytometric analysis (Becton 
Dickinson). 10,000 representative events w e r e collected at FL-1 channel in a 
log scale for e a c h of the samples herein. Signals resulted from the labeled 
D N A breaks w e r e evaluated a n d presented as a histogram using the WinMDI 
software. 
2.6.3.4 DNA Fraamenfafion Reaction 
i) G e n o m i c D N A Extraction 
Cells (1 X 106) obtained following the indicated periods of drug(s) treatment 
w e r e resuspended in 400 |LII cell lysis buffer with 10 |LII proteinase K (20 mg/ml) 
a d d e d ; a n d kept at 37°C overnight for complete digestion. O n the next day, 
150 |Lil saturated sodium chloride solution w a s introduced; the samples were 
mixed vigorously by vortex. Centrifugation at 14,000 r p m (Eppendorf) for 20 
minutes w a s applied to collect the supernatant. After so, g e n o m i c D N A w a s 
extracted with an equal volume of 25:24:1 phenol-chloroform-isoamyl 
alcohol twice. The extracted D N A w a s then precipitated with 1 ml ice-cold 
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absolute� ethanol� at� -20。C� for� 30� minutes.� The� D N A� so� resulted� w a s�
recovered�by�centrifugation,�rinsed�with�cold 7 5 % ethanol o n c e a n d allowed 
to air dry. Lastly, the D N A samples w e r e dissolved in 20 jul TE buffer 
containing 0.2 m g / m l R N a s e A. 
ii) A g a r o s e G e l 曰ectrophoresis�
2 % (w/v) agarose gel w a s then prepared by melting 1 g agarose in 50 ml 1 x 
TBE buffer containing 0.5 lag/ml EB. Equal a m o u n t of samples, say 20 jug, 
pre-mixed with D N A loading d y e w e r e loaded to the agarose gel; a n d 
electrophoresis w a s performed at constant voltage of 80 V for 45 minutes. 
U p o n finished, the D N A laddering pattern w a s visualized under U V illumination 
(Alpha Innotech); a n d the i m a g e w a s recorded. 
2.6.4 Western Blot Study 
2.6.4. / Whole-cell Protein Extraction 
i) Protein Preparation 
Cells (1 X lO) grown in 100 mrn^ Perti dishes (Iwaki) w e r e disrupted in 300 jil 
lysis buffer on ice for 30 minutes. The lysates w e r e then boiled for 10 minutes; 
a n d centrifuged at 14,000 rpm (Eppendorf) for 15 minutes. In the end, the 
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supernatants w e r e saved for Western blot study. 
2.6.4.2 Mitochondrial and Cytosolic Fraction Protein Extraction 
i) Protein Preparation 
Control a n d treated panels of cells (4 x lO) in 150 c m ^ culture flasks (Iwaki) 
w e r e harvested, w a s h e d a n d resupended in 50 |LII buffer A (containing 0.5 
m g / m l digitonin). The resulting cell suspensions w e r e mixed by vortex; a n d 
then centrifuged at 10,000 r p m (Eppendorf) for o n e minute. The 
supernatants (SI) w e r e collected. After that, the pellets remained were 
resupended in 50 |LII buffer B (containing 5 m g / m l digitonin). Again, the cell 
suspensions w e r e mixed; a n d centrifuged at 10,000 r p m (Eppendorf) for o n e 
minute for n e w supernatants (S2). SI a n d S2 isolated herein represented the 
cytosolic a n d mitochondrial fractions, respectively (Ko et a/., 2000). 
ii) Protein Quantification a n d Standardization b y B C A assay 
B C A assay w a s a d o p t e d to determine the protein concentration of samples 
in a 96-well plate format. In the first place, protein standards with different 
amounts of BSA (0, 2, 4, 6, 8 a n d 1�〇�mg/ml)�were�introduced�to�the�wells.� For�
the�part�of�testing�samples,�1 |LII protein w a s mixed with 9 |LII PBS in e a c h single 
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well.� Three�replicates�of�BSA�standards�a n d� samples�we r e�included�totally.�
After�so,�200� jul�B C A� mixture� consisting� of�B C A� a n d� CuS〇4.5H2〇�solutions�
pre-mixed�in�a�ratio�49:1�w a s�a d d e d .� The�plate�w a s�then�left�at�37^0�for�30�
minutes;� absorbance� w a s� recorded� at� 540� n m� by� a� microplate� reader�
(Bio-Rad).� In� doing� so,�a� standard� curve� w a s� established,�with� x-axis�
representing� the� concentration� of� BSA� a n d� the� y-axis� as� the� measured�
absorbance�values�at�540�n m .� A n�equation�w a s�thereby�developed�for�the�
direct�calculation�of�protein�quantity�present�in�the�samples.� Fig�2.1�s h o w e d�
a�standard�BSA�curve.�
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Fig 2.6.4.1 BSA protein standard curve plotted for protein concentration 
estimation. 
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iii)�SD S - P o l y a c r y l a m i d e� G e l 日ectrophoresis�
The� apparatus� of� Mini-Protean� III�cell� (Bio-Rod)� for S D S - P A G E w a s set u p 
according to the supplier's instructions. With reference to the molecular 
weight of the target protein(s), different percentages of resolving gels a n d 
stacking gel w e r e e m p l o y e d . The gel composition w a s given in Table 2.3. 
Resolving Gel Stacking Gel 
10% 12% 15% 5% 
dd.H20 1.90 ml 1.60 ml 1.10 ml 1.40 ml 
4 X resolving gel buffer 1.35 ml 1.35 ml 1.35 ml — 
4 X stacking gel buffer — — — 0.25 ml 
30% acrylamide 1.70 ml 2.00 ml 2.50 ml 0.33 ml 
TEMED 20 
^ ^ ^ ^ 2jLll 
Table 2.3 The ingredients needed to prepare the resolving and stacking protein 
gels. 
Protein samples obtained in the earlier time w e r e boiled in a thermocycler 
(Progene) for five minutes for heat denaturation. Subsequently, a n aliquot 
of the denatured supernatant containing 30 jug protein, mixed with SDS 
loading dye, w a s resolved by a SDS-polyacrylamide�gel.曰ectrophoresis� w a s�
performed�at�a�constant�voltage�of�220 V for 45 minutes. U p o n finished, the 
gel w a s r e m o v e d from the electrophoresis cell; a n d passed to the 
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(PVDF) m e m b r a n e (Millipore) w a s rehydrated with absolute methanol; a n d 
then immersed in the E-blot buffer. 1 m m filter paper ( W h a t m a n ) w a s 
soaked together in the E-blot buffer for use. The tank transfer system for 
electro-blotting w a s next assembled in the sequence: cathode, fiber p a d , 3 x 
filter paper, SDS-polyacrylamide gel, P V D F m e m b r a n e , 3 x filter paper, fiber 
p a d , a n o d e . At last, electro-blotting w a s performed with a constant current 
at 200 m A for o n e hour to ensure complete transfer of proteins onto the PVDF 
m e m b r a n e . 
V) Probing of Proteins with Antibodies 
As the procedure got accomplished, the m e m b r a n e w a s brought to 
non-specific blocking with 10% (v/v) slimmed milk in PBS-T for two hours at 
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r o o m temperature. Later on, the blot w a s probed with specific primary 
antibody at overnight. O n the next day, the antibody w a s descanted; 
the blot w a s w a s h e d with PBS-T three times for 15 minutes e a c h . 
HRP-conjugated secondary antibody w a s then loaded to the blot for another 
hour at 4°C. (Antibodies used so far w e r e listed in Table 2.1.) In final, the 
blot w a s w a s h e d with PBS-T twice; a n d subjected to the e n h a n c e d 
chemiluminescence assay ( A m e r s h a m Biosciences). 
vi) E n h a n c e d C h e m i l u m i n e s c e n c e (ECL) Detection 
ECL assay w a s c o n d u c t e d by mixing the ECL reagents o n e a n d two in a ratio 
of 25:1, as stated in the protocol. The m e m b r a n e w a s exposed to the ECL 
reagent mixture for o n e minute at r o o m temperature. Following that, the 
whole m e m b r a n e w a s preserved b e t w e e n two layers of transparency; a n d 
developed on Fuji Medical x-ray film (Fuji). Films w e r e processed in a film 
processor (Kodak). 
2.6.5 Caspase Activity Determination 
Quantitative m e a s u r e m e n t of caspase activity w a s achieved using the 
ApoLogix Carboxy-Fluorescein Caspase Detection Kit (Cell Technology). In 
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the assay, firstly, cells (3 x 明� wer e�harvested,�w a s h e d� a n d� resuspended�in�
300� complet e� m e d i u m ,�with� 10� 1�x�working� FAM-peptide-FMK-solution�
a d d e d .� The� resulting� suspensions� we r e� kept� at 37°C in the dark with 
constant shaking for a n hour. Shortly after, the samples w e r e rinsed with the 
w a s h buffer twice; a n d then p r o c e e d e d to the FACSort flow cytometric 
detection (Becton Dickinson). Fluorescence signals w e r e mainly collected 
at FL-1 channel to acquire 10,000 events. 
2.6.6 Mitochondrial Transmembrane Pofenfiol Depolarization 
Measurement 
Cells (3 X 105) from the respective control a n d treated groups w e r e collected; 
a n d subsequently w a s h e d with PBS twice. The cell pellets w e r e next 
resupended in 500 |LII plain m e d i u m containing 2.5 ^iM JC-1 dye; a n d the 
suspensions w e r e allowed to stand in the dark for 15 minutes at room 
temperature. Eventually, the mitochondrial depolarization patterns of the 
cells w e r e examined by m e a n s of FACSort flow cytometry (Becton Dickinson). 
Channels FL-1 a n d FL-3 w e r e e m p l o y e d for a simultaneous detection of green 
a n d red fluorescence signals from the m o n o m e r i c a n d aggregated forms of 
JC-1, respectively. 
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2.6.7 in vivo Animal Study 
i) in vivo d r u g administration 
1 X 107 h u m a n h e p a t o m a cells, H e p G 2 , in 0.2 ml PBS w e r e subcutaneously 
inoculated b e t w e e n the scapulae of the m a l e n u d e mice. After solid tumor 
formation (i.e. tumor volume reached 200 m m ^ ) , the tumor-bearing n u d e 
mice w e r e then randomized into three experimental groups, e a c h having 8 
mice. The control mice w e r e given 0.2 ml 5 % ethanol e a c h on alternate 
days for 30-day duration. While, the 2 treatment groups w e r e intra-venously 
injected with the doses of 20 m g / k g / d a y a n d 30 m g / k g / d a y of drug 
(Leachianone A), respectively. 
ii) P l a s m a E n z y m e Activities Evaluation 
In the e n d of the experiment, all the animals w e r e sacrificed; their tumors 
w e r e dissected a n d weighed. The tumor inhibitory rates w e r e calculated 
from the formulae: ( m e a n tumor weight of control n u d e mice - m e a n tumor 
weight of treated n u d e mice) / m e a n tumor weight of control n u d e mice x 
100 % . Plasma levels of creatine kinase (CK), lactate dehydrogenase (LDH), 
alanine transaminase (ALT) a n d aspartate transaminase (AST) in all three 
groups of mice were also determined at the s a m e time, as instructed by the 
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assay protocol provided (Stanbio). In short, indicated volumes of plasma 
samples w e r e incubated with the test reagents at 37oC for o n e to three 
minutes. Then, the absorbance w a s read at a particular wavelength by a 
spectro-photometer (Beckman), depending on the type of assay performed. 
The enzymatic activities w e r e calculated using the formula: 
plasma enzymatic activity (U/L) = (AA per min x TV x 1000)/ (6.22 x LP x SV), where 
A A per min = change in absorbance per minute at a particular wavelength, 
TV = total reaction volume (in ml), 
LP = light path, 
SV 二�sample�volume,�
6.22 = milli-molar absorptivity of NADPH, and 
1000 = conversion of units per ml to per liter. 
In another w a y round, the formula w e r e expressed as: 
CK (U/L) = A A per min x 8200 
LDH (U/L) = A A per min x 3376 
AST (U/L) = A A per min x 1768 
ALT (U/L) = A A per min x 1768 
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2.6.8 Two-Dimensional Gel Electrophoresis 
2.6.8.1 SamDie Preparation 
Soon after the drug(s) incubation, the w a s h e d cell pellets (1 x 10^) were 
disrupted in 300 jul denaturing lysis buffer on ice for 30 minutes. Cellular 
debris w a s r e m o v e d by centrifugation (Eppendorf) at 14,000 r p m for 10 
minutes to release the protein content at A^C. S a m p l e solutions resulted 
w e r e then subjected to the treatment with 2 D Clean-up kit (Amersham 
Biosciences) to eliminate any interfering substances. 
The clean-up process w a s d o n e in the w a y as described in the user's manual 
with s o m e modifications. It b e g a n with mixing the samples with three 
volumes of precipitant by vigorous vortex, followed by standing on ice for 15 
minutes. Thereafter, an equal volume of co-precipitant w a s introduced to 
the mixtures; a n d the proteins were precipitated out by centrifugation at 
14,000 rpm (Eppendorf) for 10 minutes at . The supernatants were 
aspirated immediately. While, the pellets were w a s h e d with 200 jul 
co-precipitant once; a n d then resuspended in 50 jul�dd.H2〇.1�ml�pre-chilled�
wash�buffer,�together�with�5� wash�additive,�w a s�a d d e d�to�the�pellet.� The�
solution� w a s� left�at -20°C for o n e hour. Afterwards, the proteins were 
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precipitated out again by centrifugation at 14,000 r p m (Eppendorf) for 10 
minutes at . The supernatants w e r e decanted; whereas the pellets w e r e 
dried briefly. Eventually, the dried pellets w e r e solubilized in 250 i^l 
rehydration buffer; a n d applied directly to the Immobiline Drystrip gel 
( A m e r s h a m Biosciences). 
2.6.8.2 First Dimension Electrophoresis - Isoelectric Focusing flEFI 
Before isoelectric focusing, protein concentration of the samples w a s 
estimated with the use of 2 D Q u a n t kit ( A m e r s h a m Biosciences), which w a s 
compatible to most of the detergents a n d reductants, like urea, C H A P S a n d 
DTT, etc. Accordingly, equal amounts of proteins, say 300 |ug, w e r e loaded 
onto the corresponding strip holders. lEF Immobiline Drystrips (13 c m ; linear 
p H 3-10 gradient), with gel facing d o w n , w e r e subsequently inserted into the 
grooves. A n y air bubbles trapped in-between the gel a n d the holder were 
carefully dispersed. After a while, 1 ml IPG Cover Fluid (Amersham 
Biosciences) w a s evenly distributed onto the entire strip, so as to minimize 
sample evaporation a n d urea crystallization. 
The strips in the strip holders were h e n c e placed on the Ettan IPGphor II 
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system platform ( A m e r s h a m Biosciences). Rehydration a n d protein 
absorption to the strips w e r e initiated under a low voltage of 30 V 
(step-and-hold) for 12 hours. Isoelectric focusing w a s then followed with the 
condition: 500 V (step-and-hold) for o n e hour, 1,000 V (step-and-hold) for o n e 
hour a n d 8,000 V (step-and-hold) for two hours. The current used w a s limited 
to 50 |LIA per gel strip; a n d the temperature w a s maintained at� 20。C�
throughout�the�experiment.� The�total�product�of�time�x�voltage�w a s�set�at�17�
Vhrs for e a c h strip. 
2.6.8.3 Second Dimension Electrophoresis - SDS-Polvocrvlamide Gel 
Electrophoresis /SDS-PAGEI 
The focused lEF strips w e r e next p r o c e e d e d to the two-step equilibration 
procedure, in which the strips w e r e incubated in equilibration buffers A 
(containing 1% DTT) a n d B (containing 2.5% lAA) sequentially for 15 minutes at 
r o o m temperature with gentle rocking. O n completion, excessive 
equilibration buffer w a s tapped off; the equilibrated lEF strips were ready for 
the second-dimension run. 
In the second-dimension gel electrophoresis, the SE 600 Ruby Standard 
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Vertical Unit ( A m e r s h a m Biosciences) w a s utilized. O n c e the 
SDS-polyacrylamide gels (12%) w e r e prepared, the lEF strips w e r e put d o w n 
onto the gel surface; a n d a piece of filter p a p e r s o a k e d with protein marker 
(Invitrogen) w a s positioned aside for size indication. 1 ml p r e - w a r m e d 
sealing agarose solution w a s overlaid onto the gels; a n d allowed to solidify for 
five minutes at r o o m temperature, in order to fill the narrow g a p s b e t w e e n 
the gel e d g e s a n d lateral spacers to prevent leakages. W h e n all these w e r e 
finished, electrophoresis w a s carried out under cooling at a constant voltage 
of 200 V for six hours, until the b r o m o p h e n o l blue dye-front r e a c h e d the 
b o t t o m of the gel. 
2.6.8.4 Silver Staining 
After electrophoresis, protein spots o n the gels w e r e visualized by a silver 
staining m e t h o d . The general procedures w e r e tabulated b e l o w (Table 2.4). 
Amount for 
Step Solution Duration 
— Each Gel 
fixation solution 
fixation (10% (v/v) acetic acid 250inl overnight 
and 40% (v/v) ethanol) 
sensitizing solution 
sensitizing 250ml 1 hr 
(6.8% (w/v) sodium acetate, 
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5 % (w/v) sodium thiosulphate 
a n d 30% (v/v) ethanol) 
washing nano pure water� �50〇ml� 5 x 8�mins�
silver nitrate solution 
silver�nitrate� 2〇0ml� 1�hr�
(2.5% (w/v) silver nitrate) 
washing nano pure water� �5 0 0 m l� 4x�1�min�
developing solution� depends,�until�
developing (2.5% (w/v) sodium carbonate 250ml protein spots 
and 0.1 % (v/v) 37% formaldehyde) appear 
stopping solution 
stopping 250ml 30 mins 
(1.5% (w/v) EDTA) 
washing nano pure water ~ 500ml 2 x 5 mins 
storage solution 
up to 1 month 
storage (12% (v/v) acetic acid 250ml 
at4。C�
and 40% (v/v) ethanol) 
Table 2.4 The procedures Involved In a standard silver staining process. 
The d e v e l o p e d gel i m a g e s w e r e soon s c a n n e d a n d recorded by the I m a g e 
Scanner II ( A m e r s h a m Biosciences), e q u i p p e d with the L a b S c a n software 
(version 3.0) ( A m e r s h a m Biosciences). To tackle with the problems of 
experimental variations, comparative analysis w a s m a d e b e t w e e n replicated 
sets of control a n d treated samples, using the c o m p u t e r software 
ImageMaster 2 D Platinum (version 5.0) ( A m e r s h a m Biosciences). Protein 
spots with differential expression pattern (at least two-fold difference) 
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identified w e r e excised out manually; a n d kept frozen at�-80。C�until�further�
processing.�
2.6.9 Mass Spectrometry Preparation 
2 . 6 . 9 . / Destainina and Trypsin Digestion 
Subsequent� preparation� work� for�the� peptide� mas s� fingerprinting� involved�
multiple� steps,�as� depicted� as� follows.� First�of�all,�100� fresh� destaining�
solution� w a s� introduced� to� the� gel� slices,�incubated� for� 15� minutes� with�
frequent�shaking�a n d�agitation.� As�a�clear�b a c k g r o u n d�w a s�attained,�they�
w e r e�w a s h e d�with�a�large�v o l u m e�of�n a n o�pure�water�three�times.� After�that,�
the�gel�pieces�w e r e�imme r s e d�in�200�m M� N H 4 C O 3�solution�for�10�minutes;�this�
process�w a s� repeated� o n c e .� The� equilibration�solution�w a s� discarded.� In�
the� m e a n t i m e ,�300 |LII 100% (v/v) A C N w a s a d d e d to dehydrate the gel 
masses for five minutes twice. At this point, shrinked white a n d o p a q u e spots 
w e r e left behind. They w e r e dried in the S p e e d V a c concentrator (Savant) 
shortly for o n e to t w o minutes. Lastly, the gel blocks w e r e digested by trypsin 
in the presence of 50 m M N H 4 C O 3 at�30。C�overnight.�
2 . 6 . 9 . 2 Peptide Extraction 
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The tryptic digests containing mixtures of peptides w e r e subsequently mixed 
with 50 |il 50 m M N H 4 C O 3 ; all the liquids w e r e saved a n d transferred to a n e w 
tube. Further extractions w e r e d o n e with 100 )LI  5 0 % (v/v) A C N / 5 % (v/v) TFA 
solution twice; a n d 50 fil 100% (v/v) A C N o n c e , for 10 minutes e a c h time in an 
ultra-sonic water bath. Finally, all the supernatants w e r e pooled together; 
a n d brought to the S p e e d V a c concentrator (Savant) for drying at I60C�f〇「�
five�hours.�
2 . 6 . 9 . 3 Desalfina of Peptide Mixture 
Next,�the�dried�samples�were�reconstituted�with�10 0.1% TFA (v/v) solution. 
Purification a n d concentration procedures w e r e carried out with the aid of 
ZipTip C-18 Pipette Tips (Millipore). For use, ZipTip tips (Millipore) w e r e wetted 
with 10 i^l 5 0 % (v/v) A C N solution twice; a n d then w a s h e d with 10 \i\ 0.1% TFA 
(v/v) solution three times ready for sample binding. Peptides were b o u n d 
onto the tips by drawing a n d dispensing the content for 20 cycles. Later on, 
the tips w e r e w a s h e d three times; the b o u n d peptides were eluted in 2 50% 
(v/v) A C N / 0.1% (v/v) TFA solution. In the end, 1 ]i\ saturated C H C A matrix 
w a s loaded to the samples; the whole mixtures were thereby spotted directly 
onto the MALDI-target (Applied Biosystems). 
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Data for e a c h sample spot on the M A L D I plate (Applied Biosystems) w e r e 
acquired employing the 4700 Proteomics Analyzer a n d 4700 Explorer 
softwares (Applied Biosystems). C o m b i n e d M S a n d M S / M S analysis w a s 
basically c o n d u c t e d by the M a s c o t based G P S Explorer Software R e m o t e 
Access Client (Applied Biosystems), in which the error tolerance for peptide 
mass w a s set to b e 50 p p m ; a n d the possible missed cleavage of trypsin w a s 
one. For M A L D I peptide m a p p i n g , both the Swiss-Prot (http://us.expasy.org) 
as well as NCBInr (http://www.ncbi.nlnn.nih.gov) databases w e r e searched. 
Only as the proteins got m o r e than four peptides m a t c h e d w e r e considered 
as significant. 
2,6.10 Real-Time PCR 
i) R N A Extraction 
Subsequent to the drug(s) exposure, cells (1 x lO) w e r e rinsed o n c e with PBS; 
a n d lysed directly in 2 ml TRIzol reagent (Invitrogen) on ice for five minutes. 
Then, 400 chloroform (Invitrogen) w a s introduced to the lysates; the 
mixtures w e r e mixed vigorously for 15 seconds a n d let stand on ice for three 
minutes. After that, the samples were centrifuged at 14,000 rpm (Eppendorf) 
for 15 minutes at 4°C: three layers were thus formed: a lower red chloroform 
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layer, a n inter-phase layer as well as a n u p p e r colourless a q u e o u s layer 
containing R N A exclusively. Colourless p h a s e w a s aspirated to a n e w tube 
instantly, to which 500 |il isopropanol w a s a d d e d . The solution w a s placed 
at -20°C overnight for R N A precipitation. O n the d a y after, the tube w a s 
taken to centrifugation at 14,000 r p m (Eppendorf) for 15 minutes at to 
separate R N A from the organic solvents. The R N A pellet w a s w a s h e d with 
ice-cold 7 5 % ethanol o n c e , followed by air-dried at r o o m temperature. In 
final, 30 )LI D E P C - H 2 O w a s used to dissolve the pellet ready for the c o m i n g part 
of assay. 
ii) First-Strand c D N A Synthesis 
First-strand c D N A w a s reverse-transcribed from the total R N A pool in a 
reaction catalyzed by the SuperScript-lll RT e n z y m e (Invitrogen). The 
reaction mix consisted of the c o m p o n e n t s listed below (Table 2.5). 
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5 X c D N A synthesis buffer 4 \i\ 
oligo T primer (0.05 m M ) 1 
d N T P mix (10 m M ) 2[i\ 
R N A (2 lag) x ^ il 
DTT (100 m M ) 1 jul 
R N a s e O U T (40 U/^ il) 1 i^l 
SuperScript-lll RT (200 U/|LI ) 1 i^l 
D E P C - H 2〇 ( 1 0 - X ) ]Lil 
T O T A L ^ 
Table 2.5 The ingredients needed to make up a reaction mix for the first-strand 
cDNA synthesis reaction. 
Reverse transcription reaction w a s carried out in a thermocycler (Progene), 
as started at 50°C for 60 minutes a n d terminated at 85°C for five minutes. 
W h e n d o n e , 1 R N a s e H (Invitrogen) w a s a d d e d ; the mix w a s then 
incubated at 37°C for 20 minutes. c D N A synthesized herein w a s either used 
for the real-time P C R analysis immediately, or placed at -20°C for temporary 
storage. 
iii) Real-Time P C R 
In general, all the real-time P C R assays w e r e performed in a total v o l u m e of 
20 )Lil in a 96-well plate format by the ABI PRISM 7700 s e q u e n c e detection 
system (Applied Biosystems). Reaction mixtures for e a c h assay contained 1 
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|Ltl 20 X g e n e expression assay mix (TaqMan), 9 …diluted c D N A a n d 10 |il 2 x 
universal P G R master mix (TaqMan). While, the thermocycling conditions 
w e r e set as: o n e cycle at SO^C for two minutes a n d 95�C� for�10�minutes;�40�
cycles�at�95^0� for�15�seconds� a n d 60°C for o n e minute, according to the 
guidelines from the manufacturer. 
For e a c h investigated g e n e , triplicates of experiments w e r e included to 
ensure the reproducibility of results. Relative a b u n d a n c e of the g e n e 
transcripts in samples w a s determined after normalization with the control 
g e n e , beta-actin. 
iv) D a t a Analysis 
In fact, the basis of g e n e c o p y quantification by real-time P G R fundamentally 
relied on the threshold cycle, CT, as referred to the cycle number, at which 
the fluorescence emitted e x c e e d e d the fixed threshold. CT value, as 
determined by the S e q u e n c e Detection Systems (version 1.9) (Applied 
Biosystems), w a s inversely proportional to the initial a m o u n t of target 
template. A n d , the expression level of the target gene, represented by the 
term ~ m e a n fold c h a n g e , w a s calculated from the formulae (Livak ef oL, 
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2001): 
m e a n fold change = 2-AACT, where 
A A C T = ACT of the target gene in drug-treated sample 一�ACT�of�the�target�gene�in�
the�control�sample,�and�
ACT = CT of the target gene - CT of beta-actin. 
M e a n fold c h a n g e of the target g e n e revealed its a m o u n t difference in the 
treated sample(s) relative to the control one; whereas m e a n fold c h a n g e of 
the control sample w a s set to b e one. For down-regulation of the target 
gene, the mean-fold-change value ranged from zero to one; in case of 
up-regulation, however, the value w a s greater than one. 
2.6.71 Cellular Glutathione Level Defection 
The detection of the changes in glutathione level of apoptotic cells w a s 
chiefly accomplished by the Glutathione Apoptosis Detection Kit, 
Fluorometric (Calbiochem). In a few words, cells were resuspended in 100 jul 
ice-cold cell lysis buffer; a n d continued on ice for 10 minutes. Then, the 
supernatants were pipetted to the wells of a 96-well flat-bottom microplate, 
in which 2 M C B a n d 2 |il GST reagents were present. After so, the plate 
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w a s incubated at 37^0 for 30 minutes. The fluorescence w a s subsequently 
m e a s u r e d at 380 n m / 460 n m using a fluorometer (Beckman). 
2.7 Statistical Analysis 
Values w e r e expressed as the m e a n 土�standard�deviation�(SD).� A�significant�
difference�from�the�respective�controls�for�e a c h� experimental�test�condition�
w a s�assessed�using Student's unpaired t-test, with p values of < 0.01 or < 0.05 
being regarded as statistically significant. 
—— Chapter 4 
Results and Discussion 
CHAPTER 3 
RESULTS and DISCUSSION --
CYTOTOXICITY OF FLAVONOIDS ISOLATED FROM RADIX SOPHORAE 
3.1 Screening of Cytotoxic Flavonoids f rom Radix Sophorae 
Given Radix Sophorae being frequently prescribed against liver diseases in 
alternate clinical practice, w e attempted to screen for the active principle(s), 
which a c c o u n t e d for these medicinal effects herein. Previously, a 
bioassay-guided fractionation a n d purification of Radix Sophorae w a s 
c o n d u c t e d by our group, from which six flavonoid constituents w e r e found to 
exhibit potent cytotoxicities on h e p a t o m a cells in vitro (unpublished data). 
Their identities w e r e revealed by nuclear magnetic resonance (NMR) a n d 
mass spectrometric (MS) analyses. Their structures are s h o w n in Fig. 3.1.1. 
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Fig. 3.1.1 Structures of 6 bioactive flavonoids purified from the Radix Sophorae. 
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A m o n g t h e m , the t w o c o m p o n e n t s , n a m e l y L e a c h i a n o n e A a n d 
Sophoraflavone 丄�w e r e�our�study�targets.� Their�anti-tumor�activities�w e r e�first�
ac c e s s e d�by�their�ability�to�suppress�growth�of�h e p a t o m a� cells in vitro. 
M T T�assay�is�a�standard�quantitative�colorimetric�test�for�the�determination�of�
cell�survival� a n d� proliferation� ( M o s m a n n et al.,� 1983).� It�is�ba s e d� on� the�
capability� of� a� mitochondrial� d e h y d r o g e n a s e e n z y m e to cleave the 
tetrazolium rings of the M T T salt; a n d form dark purple formazan crystals, which 
are largely i m p e r m e a b l e to cell m e m b r a n e s , thereby resulting in their 
accumulation within the healthy cells (Pagliacci et al., 1993). In this sense, 
the n u m b e r of viable cells is directly proportional to the level of the formazan 
products generated. 
3.2 Cytotoxicity of Leachianone A on Human Hepatoma Cell Lines 
Initially, the cytotoxicity of Leachianone A on H e p G 2 cells a n d its resistant 
counterpart R H e p G 2 cells w a s investigated. Under the experimental 
conditions, Leachianone A treatment c a u s e d a n inhibition o n the proliferation 
of both h e p a t o m a cells dose-dependently. The ICso (50% inhibitory 
concentration) values of 24-, 48- a n d 72-hour incubations for H e p G 2 a n d 
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R H e p G 2 cells w e r e calculated as 6.9 jug/ml, 3.4 ^ ig/ml a n d 2.8 ng/ml; as well as 
3.8 iLig/ml, 1.4 jug/ml a n d 1.4 ^ g/ml respectively, from the dose-response curve 
(Fig. 3.2.1 & 3.2.2)• In both cases, profound cytotoxic activity of Leachianone 
A w a s observed at 48-hour culture. 
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Treatment of Leachianone A on HepG2 Cells at Various 
Concentrations for Different Time Periods 
120 I — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — 
1 0 0 ^ 
f 二 我 
CO \ —O—24 hours 
I 40 hours 
12。� ^�
( ：；� 4� 6� �^ 10� 12� fa� lb� 18� 2D�
Leachianone A Concentration (ug/ml) i 
Fig. 3.2.1 Effect of Leachianone A on the proliferation of HepG2 cells. 
Cells (1 X ICH) were seeded in 96-well plates and incubated with different 
concentrations of Leachianone A for 24, 48 a n d 72 hours at 5 %� C〇2.� Cell�
viability�wa s�determined�by�MTT�assay.� Results�are�m e a n 土�SD�of�5�determinations.�
Treatment of Leachianone A on RHepG2 Cells at Various 
Concentrations for Different Time Periods 
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Fig. 3.2.2 Effect of Leachianone A on the proliferation of RHepG2 cells. 
Cells (1 X 104) were seeded in 96-well plates and incubated with different 
concentrations of Leachianone A for 24, 48 and 72 hours at 37°C, 5 %� C〇2.� Cell�
viability�was�determined�by�MTT�assay.� Results�are�m e a n 土�SD�of�5�determinations.�
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3.3 Cytotoxicity of Leachianone A on Human Normal Liver Cell Line 
To define if the c o m p o u n d exerted its action specifically on the tumor cells, a 
h u m a n normal liver cell line WRL-68 w a s also included as a parallel experiment. 
U p o n addition of increasing concentrations (0 jug/ml - 20 jug/ml) of 
Leachianone A for 48 hours, there w a s a dose-dependent reduction in the cell 
viability, with a n IC50 value found to b e 9.5 lug/ml (Fig. 3.3.1). Despite this, the 
percentage of cell survival still maintained high u p at 9 5 % w h e n challenged 
with the effectual dosages (1.4 ]ig/ro\ - 2.8 lug/ml) of Leachianone A against 
cancer cells. 
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Treatment of Leachianone A on WRL-68 Cells at Various 
Concentrations for 48 Hours 
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Fig. 3.3.1 Ef fect of Leachianone A on the prol i ferat ion of WRL-68 cells. 
Cells (1 X� 1〇4)�were� seeded� in� 96-well� plates� and� incubated� with� different�
concentrations�of Leachianone A for 48 hours at 37°C, 5 % CO2. Cell viability w a s 
determined by MTT assay. Results are m e a n 土�SD�of�5�determinations.�
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3.4 Cytotoxicity of Sophoraflavone J on Human Hepatoma Cell Line 
Next, the cytotoxicity of Sophoraflavone J on H e p G 2 cells w a s examined. 
From the experiment, Sophoraflavone J brought about 5 0 % cell death at a 
concentration of 8.1 jug/ml following 24-hour, 5.5 |ug/ml following 48-hour a n d 
5.3 i^g/ml following 72-hour incubations (Fig. 3.4.1). Again, the data indicated 
that the maximal inhibitory effect w a s attained at 48 hours. 
Because of the scarce a m o u n t of Sophoraflavone J extracted, the 
cytotoxicity test on R H e p G 2 cells w a s lacking at the m o m e n t . 
3.5 Cytotoxicity of Sophoraflavone J on Human Normal Liver Cell Line 
In the situation of WRL-68 cells, similarly, presence of Sophoraflavone J arrested 
cell growth after 48 hours. 5 0 % survival rate of cells w a s detected at a 
concentration of 8.8 lug/ml, being m u c h higher than the o n e (5.5 jag/ml) for 
H e p G 2 cells (Fig. 3.5.1). 
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Treatment of Sophoraflavone J on HepG2 Cells at Various 
Concentrations for Different Time Periods 
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Fig. 3.4.1 Effect of Sophoraf lavone J on the prol i feration of HepG2 cells. 
Cells (1 X 104) were seeded in 96-well plates and incubated with different 
concentrations of Sophoraflavone J for 2 4 48 and 72 hours at 37°C, 5 % CO2. Cell 
viability w a s determined by MTT assay. Results are m e a n 土�SD�of�5�determinations.�
Treatment of Sophoraflavone J on WRL-68 Cells at Various 
Concentrations for 48 Hours 
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Fig. 3.5.1 Effect of Sophoraflavone J on the proliferation of WRL-68 cells. 
Cells (1 X 104) were seeded in 96-well plates and incubated with different 
concentrations of Sophoraflavone J for 48 hours at 37oC, 5 % CO2. Cell viability w a s 
determined by MTT assay. Results are m e a n 土�SD�of�5�determinations.�
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3.6 Cytotoxicities of Cisplatin and Taxol on Human Hepatoma as well 
as Normal Liver Cell Lines 
Aside from these, s o m e conventional anti-cancer agents, for instances 
cisplatin a n d taxol, w e r e assayed herein to allow comparisons with the two 
potential candidates. The former one, cisplatin, is well-known as a 
D N A - d a m a g i n g agent; it binds primarily to the guanine residues in D N A to 
form intra- a n d inter-strand adducts; as well as DNA-protein cross-linking 
complexes (Huang et al., 1994, W a n g et al., 2006). Cisplatin-modified 
adducts always c h a n g e the conformation of DNA-attracting nuclear proteins 
severely, especially those containing high mobility group d o m a i n , so that the 
D N A buried inside these proteins is poorly repaired (Zombie ef oL, 1996). While, 
the action of taxol is rather distinct. This natural diterpenoid attaches on the 
p-subunit of tubulin; a n d promotes the assembly of stable but non-functional 
micro-tubule bundles, which ultimately interfere the mitosis in G2/ M-phase 
junction (Jordan ef al., 1996, Frankel et al., 1997, Rieder et al., 2000). 
Likewise, various concentrations of cisplatin a n d taxol�(〇�juM�—�100�jiM)�were�
introduced�to�the�H e p G 2 ,�R H e p G 2� a n d WRL-68 cells continued for 48 hours. 
At the e n d of the incubation period, cell proliferation w a s measured using MTT 
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assay. The drug concentrations required to inhibit cell growth by 5 0 % w e r e 
listed b e l o w (Table 3.1). 
Cisplatin Taxol 
HepG2 cells 12.5 |LIM 6 |LIM 
RHepG2 cells 1 7 — 13 |IM 
WRL-68 cells 23.5 )LIM 6 ^M 
Table 3.1 A summary of the results from cell viability assays on the 48-hour 
exposure of anti-cancer drugs, cisplatin and taxol, to human hepatoma cells and 
normal liver cells. 
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Treatment of Cisplatin on HepG2 Cells at Various Concentrations 
for 48 Hours 
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Fig. 3.6.1 Effect of cisplatin on the proliferation of HepG2 cells. 
Cells (1 X ICH) were seeded in 96-well plates a n d incubated with different 
concentrations of cisplatin for 48 hours at 37oC, 5 %� C〇2.� Cell� viability� was�
determined�by�MTT�assay.� Results�are�m e a n 土�SD�of�6�determinations.�
Treatment of Taxol on HepG2 Cells at Various Concentrations 
for 48 Hours 
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Fig. 3.6.2 Effect of taxol on the proliferation of HepG2 cells. 
Cells (1 X 104) were seeded in 96-well plates and incubated with different 
concentrations of taxol for 48 hours at 37oC, 5 % CO2. Cell viability was determined by 
MTT assay. Results are m e a n 土�SD�of�6�determinations.�
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Treatment of Cisplatin on RHepG2 Cells at Various Concentrations 
for 48 Hours 
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Fig. 3.6.3 Effect of cisplatin on the proliferation of RHepG2 cells. 
Cells (1 X 104) were seeded in 96-well plates a n d incubated with different 
concentrations of cisplatin for 48 hours at 37°C, 5 %� C〇2.� Cell� viability� was�
determined�by�MTT�assay.� Results�are�m e a n 土�SD�of�6�determinations.�
Treatment of Taxol on RHepG2 Cells at Various Concentrations 
for 48 Hours 
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Fig. 3.6.4 Effect of taxol on the proliferation of RHepG2 cells. 
Cells (1 X� 1〇4)�were� seeded� in� 96-well� plates� and� incubated� with� different�
concentrations�of�taxol�for�48�hours�at�Z K . 5 % CO2. Cell viability was determined by 
MTT assay. Results are m e a n 土�SD�of�6�determinations,�
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Treatment of Cisplatin on WRL-68 Cells at Various Concentrations 
for 48 Hours 
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Fig. 3.6.5 Effect of cisplatin on the proliferation of WRL-68 cells. 
Cells (1 X ICH) were seeded in 96-well plates and incubated with different 
concentrations of cisplatin for 48 hours at Zl^C, 5 % CO2. Cell viability w a s 
determined by MTT assay. Results are m e a n 土�SD�of�6�determinations.�
Treatment of Taxol on WRL-68 Cells at Various Concentrations 
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Fig. 3.6.6 Effect of taxol on the proliferation of WRL-68 cells. 
Cells (1 X ICH) were seeded in 96-well plates and incubated with different 
concentrations of taxol for 48 hours at Z I C . 5 % CO2, Cell viability w a s determined by 
MTT assay. Results are m e a n 土�SD�of�6�determinations.�
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3.7 Conclusion 
Tabulated in the following w e r e the IC50 values of different combinations of 
cells a n d drugs, as determined by the M T T assay (Table 3.2). 
Leachianone A Sophoraflavone J Cisplatin Taxol 
产 “ I � I I 
24 48 72 24 48 72 
48 hours 48 hours 
hours hours hours hours hours hours 
HepG2 15.75 7.76 6.39 18.49 12.56 12.10 
12.5� 6�^ M�
cells |LIM FIM LAM FIM |LIM 
RHepG2 8.68 3.20 3.20 
--- --- --- 17 |iM 13 |iM 
ceils }iM |UM I^M 
WRL-68 21.69 20.10 
--- --- --- --- 23.5 |iM 6 |uM 
cells I |liM t^ M 
Table 3.2 A summary of the results from cell viability assays on the exposure of 
Leachianone A, Sophoraflavone J and anti-cancer drugs, cisplatin and taxol, to 
human hepatoma cells and normal liver cells for different time periods. 
Remarks: 
Conversion of the units from |ag/ml into )LIM w a s b a s e d o n the equation: 
m a s s (in \xg)/ molar mass]/ v o l u m e (in ml) = molarity (in |LIM), w h e r e 
the molar masses of Leachianone A a n d Sophoraflavone J = 438 
All in all, both Leachianone A a n d Sophoraflavone J rendered potent 
cytotoxic activities o n the h u m a n h e p a t o m a cell lines H e p G 2 a n d R H e p G 2 , in 
a time- a n d d o s e - d e p e n d e n t m a n n e r (Fig. 3.2.1, 3.2.2 & 3.3.1). The most 
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prominent growth-suppressing action, however, a p p e a r e d at 48-hour 
exposure. W h e n c o m p a r e d to the currently e m p l o y e d anti-cancer drugs, 
cisplatin a n d taxol, Sophoraflavone J presented a c o m p a r a b l e degree of cell 
growth inhibition; whereas Leachianone A o w n e d a m u c h higher efficacy in 
terms of cytotoxicity (Fig. 3.6.1 - 3.6.4). In consideration with the normal liver 
cell line WRL-68, treatments of Leachianone A a n d Sophoraflavone J for 48 
hours inevitably induced certain extents of cell loss, dose-dependently (Fig. 
3.4.1 & 3.5.1). Yet, such toxicity w a s relatively inconsequential at their 
effective dosages against h e p a t o m a cells. In fact, this kind of non-specificity 
w a s also displayed in the applications of cisplatin a n d taxol (Fig. 3.6.5 & 3.6.6). 
For this reason, Leachianone A a n d Sophoraflavone J still merited our in-depth 
research on their action mechanism(s) a n d possible therapeutic use(s) in liver 
cancer, if any. 
—— Chapter 4 
Results and Discussion 
CHAPTER 4 
RESULTS and DISCUSSION --
MECHANISTIC STUDY OF LEACHIANONE A-INDUCED CELL DEATH IN 
HEPATOMA CELLS. HepG2 and RHepG2 
4.1 Promotion of Cell Cycle Arrest 
To date, numbers of different approaches are a d o p t e d in liver cancer 
therapy using dietary pharmaceutical agents; o n e of t h e m is to promote cell 
cycle arrest. 
In cells, the division cycle is grossly comprised of four discrete but 
well-coordinated processes: cell growth, D N A synthesis (S phase), 
segregation of duplicated c h r o m o s o m e s as well as cell division (M phase). 
There are also g a p phases, k n o w n as Gi, which connects the completion of 
M phase to the initiation of S phase in next cycle; a n d G2, which separates 
the S a n d M phases. In response to s o m e developmental a n d 
environmental signals, cells in Gi phase sometimes temporarily or 
permanently leave the cycle; a n d enter a quiescent or arrested phase, 
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k n o w n as Go. Very often, t u m o r cells are, h o w e v e r , destined to repeat the 
cell cycle indefinitely, resulting in a n uncontrollable a n d excessive cell division. 
As such, b l o c k a g e or disruption of the cell cycle progression is r e c k o n e d as a 
feasible m e t h o d to suppress c a n c e r cell growth. 
To address this point, w e investigated the cell cycle distribution profile of 
H e p G 2 a n d R H e p G 2 cells, u p o n treatment with different d o s a g e s of 
L e a c h i a n o n e A b y propidium iodide (PI) staining. PI is a dye, which 
intercalates into the double-stranded nucleic acids a n d fluoresces strongly, 
so that D N A contents inside the cells are readily estimated ( G o d a r d ef a/., 
1999). A histogram of cell cycle analysis for untreated cells is given in Fig. 
4.1.1. 
number « I 
of cells - i 
— 
PI 
Fig. 4.1.1 A characteristic pattern of untreated cells in the sub-G 1, Gl/GO, S and 
M phases in the cell cycle analysis. 
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Referring to the results, there w a s a p e a k found in the sub-Gl phase, which 
represented the accumulation of a massive population of cells with 
hypo-diploid D N A contents, in all Leachianone A-treated panels of cells. As 
c o m p a r e d to the control, the percentage of cells in the sub-Gl fraction 
dramatically increased to 35.37% a n d 53.36% in H e p G 2 a n d R H e p G 2 cells 
respectively, following a rise in the Leachianone A concentration for 48 hours 
(Fig. 4.1.2 & 4.1.3). In spite of this, arrest at any phase of the cell cycle did not 
take place at all. Therefore, w e proposed that the growth inhibition of 
H e p G 2 a n d R H e p G 2 cells elicited by Leachianone A w a s s o m e h o w 
correlated with apoptosis rather than cell cycle arrest. 
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Fig. 4.1.2 Cell cycle analysis of HepG2 cells treated with vehicle or Leachianone 
A for 48 hours. 
Cells (3 X 105) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 ^ ig/ml (B), 20 ^ ig/ml (C) and 30 ing/ml (D) for 48 hours at 37^0, 5 % 
C〇2.� Cells�harvested�were�stained�with�PI�and�subjected�to�flow�cytometric�analysis,�
Markers�Ml,�M2,�M 3�and�M 4�corresponded�to�the�cell�fractions�at�sub-Gi,�Go/�Gi,�G2/�
M� and� S� phases,� respectively.� Results� are� representative� of� 4� independent�
experiments.�
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Fig. 4.1.3 Cell cycle analysis of RHepG2 cells treated with vehicle or 
Leachianone A for 48 hours. 
Cells (3 X 105) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 ^ ig/ml (B), 20 [xg/ml (C) and 30 ^ ig/ml (D) for 48 hours at�37。C, 5 % 
C〇2.� Cells�harvested�were�stained�with�PI�and�subjected�to�flow�cytometric�analysis.�
Markers�Ml,�M2,�M 3�and�M 4�corresponded�to�the�cell�fractions�at�sub-Gi,�Go/�Gi,�G2/�
M� and� S� phases,� respectively.� Results� are� representative� of� 4� independent�
experiments.�
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4.2 Induction of Apoptosis as Evidenced by Phosphatidylserine 
Externalization and DNA Fragmentation 
The cell cycle a n d apoptosis are intimately related. Apoptosis is a kind of 
p r o g r a m m e d cell death (PCD), in which the suicidal process is carried out in 
a n ordered s e q u e n c e a n d a regulated m a n n e r . In contrast to necrosis, 
which is considered as a r a n d o m issue as resulted from acute a n d violent 
ruptures, systematic disassembly of a cell by apoptosis reserves a 
physiological a d v a n t a g e in the cancer therapy b e c a u s e no systemic 
deleterious inflammatory responses are evoked (Satchell ef a/., 2003). That 
explains w h y exploitation of apoptotic p a t h w a y n o w e m e r g e s as a key 
m e c h a n i s m , by which cancer cells are eliminated by therapeutic drugs 
(Solaryeta/., 2002). 
In general, apoptosis is characterized by several distinctive morphological 
a n d biochemical changes in cells. The former consists of cell shrinkage, 
m e m b r a n e blebbing a n d chromatin condensation; whereas the latter 
includes the a p p e a r a n c e of phosphatidylserine (PS) on cell m e m b r a n e 
surface, D N A fragmentation, protein cleavage at specific locations a n d 
increased mitochondrial m e m b r a n e permeability, etc (Debatin et al., 2001, 
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Robertson etal.,� 2002).�
4.2. ？ Occurrence of Phosphafidylserine Externalization 
To elucidate the death type induced by Leachianone A, w e next tested for 
the occurrence of phosphatidylserine (PS) externalization onto the cell 
surface, a n event typically associated with apoptosis (van Engeland et al., 
1998). PS is a phospholipid normally restricted to the cytoplasmic surface of 
the cell m e m b r a n e in healthy cells. But, w h e n cells undergo apoptosis, PS is 
flipped a n d translocated to the outer leaflet of the cell m e m b r a n e to get 
exposed to the extra-cellular environment. As a consequence, 
m a c r o p h a g e s c o m e to surround a n d engulf these apoptotic cells, thus 
protecting organisms from inflammation, which is always a c c o m p a n i e d by 
necrosis (Bergmann etal” 2002). 
Annexin V is a 35kDa Ca2+-dependent h u m a n phospholipid-binding protein, 
which has a high affinity for PS. With a fluorophore FITC conjugated to it, 
cells with externalized PS confer a distinct green fluorescence signal, as 
detected by flow cytometry. Since PS translocation also exists during 
necrosis, a cell impermeant red fluorescence dye PI is used in the assay as an 
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indicator of m e m b r a n e structural integrity. Intact cell m e m b r a n e of viable 
a n d early apoptotic cells is simply able to exclude PI; these annexin V(-) Pl(-) 
a n d annexin V(+) Pl(-) populations cluster at the b o t t o m left a n d right 
quadrants, respectively. O n the other h a n d , loss of m e m b r a n e integrity, as 
displayed in the later stage of apoptosis or necrosis, enables the entry of PI for 
binding with D N A in the cells. Under these circumstances, both the green 
a n d red fluorescence signals are strong, i.e.�〇nnexin V(+) Pl(+); a n d cells are 
mainly localized at the top right quadrant. The general layout of cell 
distribution in annexin V/ PI staining experiment is depicted in Fig. 4.2.1.1a. 
Cells incubated with staurosporine (STS), a distinguished apoptosis-inducing 
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Fig. 4.2.1.1a Schematic diagram of cell distribution of viable, early apoptotic 
and later apoptotic/ necrotic cells in annexin V-FTIC/ PI staining experiment. 
Fig. 4.2.1.1b Density plot of cells exposed to 1 jiM staurosporine for 48 hours. 
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The results herein indicated that the proportion of annexin V-stained cells 
(signifying both the early a n d late apoptotic cells) escalated with the 
concentration of Leachianone A applied (Fig. 4.2.1.2 & 4.2.1.3). At a low 
concentration (10 lag/ml), a substantial quantity of cells w a s found present in 
the bottom right quadrant; cells w e r e primarily in the early phase of apoptosis. 
With higher concentrations (20 ^ig/ml & 30 ing/ml) introduced, a shift of the 
cell population from the bottom right quadrant to the top right quadrant w a s 
demonstrated, dictating that cells w e r e in late apoptotic/ necrotic stage. 
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Fig. 4.2.1.2 Annexin V-FTIC / PI staining of HepG2 cells treated with vehicle or 
Leachianone A for 48 hours. 
Cells (3 X 105) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 i^g/ml (B), 20 i^g/ml (C) and 30 i^g/ml (D) for 48 hours at�37。C, 5 % 
C〇2.� Cells�collected�were�passed�to�annexin V-FITC and PI staining, followed by 
flow cytometric analysis. Results are representative of 4 independent experiments. 
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Fig. 4.2.1.3 Annexin V-FTIC / PI staining of RHepG2 cells treated with vehicle or 
Leachianone A for 48 hours. 
Cells (3 X 105) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 ng/ml (B), 20 ng/ml (C) and 30 |ug/nnl (D) for 48 hours at 37^C, 5 % 
C〇2.� Cells�collected�were�passed�to�annexin V-FITC and PI staining, followed by 
flow cytometric analysis. Results are representative of 4 independent experiments. 
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4.2.2 DNA Fragmentation Defection 
D N A� fragmentation� is�broadly� documented� as�a� hallmark� of�apoptosis�
(Webb ef�a/.,�1997, 丫an et al” 2006). During the process, endonucleases are 
activated to attack the linker region between nucleosomes; and cleave the 
genomic D N A into small fragments of about 180 to 185 base pairs (bp). The 
multiple oligomers resulted are detected as an increased fluorescence 
intensity using flow cytometry in TUNEL assay; or as a laddering pattern in the 
agarose gel electrophoresis (Saraste ef al” 2000). 
4.2.2. / Terminal Deoxynucleotidyl TransferaseITdTj-mediofed dilTP 
Nick End Labeling (TUNELI Assay 
The TUNEL assay provides a quantitative fluorescence measurement of 
apoptosis-induced D N A fragmentation. This method fundamentally utilizes 
the transferase enzyme to fill the exposed 3'-hydroxyl termini in DNA strands 
directly with conjugated fluorescein-deoxyuridine triphosphate nucleotides 
(FITC-dUTP) by nicked end labeling. Given D N A degradation present in 
apoptotic cells, a multitude of these sites are available for the integration of 
the nucleotide residues into the fragmenting DNA. Conversely, 
non-apoptotic cells only incorporate a few of FITC-dUTP nucleotides, owing to 
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the lack of free 3’-hydroxyl DNA ends. The striking difference in the number 
of 3'-hydroxyl ends, which in turn affects the fluorescence intensity acquired, 
forms the basis for the identification of healthy cells and dying cells. 
Based on the TUNEL study, exposure to Leachianone A at concentrations of 
10 |Ltg/ml 20 |ag/ml and 30 lug/ml led to a considerable augment in the 
amount of cells with fragmented DNA dose-dependently (Fig. 4.2.2.1.1 & 
4.2.2.1.2). With the extreme dosage, e.g. 30 |ag/ml, over 90% of cells 
exhibited chromosomal DNA breakages. 
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Fig. 4.2.2.1.1 TUNEL assay of HepG2 cells treated with vehicle or Leachianone A 
for 48 hours. 
Cells (1 X 106) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 i^g/ml (B), 20 i^g/ml (C) and 30 lug/ml (D) for 48 hours at�37。C, 5% 
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Fig. 4.2.2.1.2 TUNEL assay of RHepG2 cells treated with vehicle or Leachianone A 
for 48 hours. 
Cells (1 X 106) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 ug/ml (B), 20 i^g/ml (C) and 30 lug/ml (D) for 48 hours at 37^0, 5% 





Results and Discussion 
4 . 2 . 2 . 2 D N A Laddering Pat fern in Agarose Gel Electrophoresis 
In the majority of cell types, a typical laddering pattern of D N A bands in 
multiples of approximately 200 bp is indicative of apoptosis. O n e of the 
limitations of TUNEL assay is that there is no way to prove the resulting D N A 
fragments are of which size. Qualitative assessment is hence needed to 
overcome this shortcoming. 
In the agarose gel electrophoresis, a characteristic laddering pattern of D N A 
was observed at concentrations of 20 i^ ig/nnl and 30 ^ ig/ml of Leachianone A 
in HepG2 cells post-48-hour drug treatment (Fig. 4.2.2.2.1 A). Similar pattern 
was noted in RHepG2 cells too, but at a lower concentration of 10|Lig/ml (Fig. 
4.2.2.2.1 B). These were in agreement with our data obtained previously from 
TUNEL assay, in which RHepG2 cells were more sensitive than HepG2 cells to 
Leachianone A treatment in terms of D N A fragmentation (Fig. 4.2.2.1.1 & 
4.2.2.1.2). Collectively, w e concluded that Leachianone A inhibited the 
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Fig. 4.2.2.2.1 Induction of DNA fragmentation In Leachianone A-treated A) 
HepG2 and B] RHepG2 cells. 
Cells (1 X 106) were incubated with vehicle only (lanes 1 & 6) and Leachianone A at 
concentrations of 10 lug/ml (lanes 2 & 7), 20 }ig/ml (lanes 3 & 8) and 30 i^g/ml (lanes 4 
& 9) for 48 hours at 5%�C〇2.� D N A� laddering�pattern�was�observed�by 2% 
agarose gel�elec什ophoresis.� lOObp�D N A�marker�(lanes�5 & 10) was positioned aside 
for size indication. Results are representative of 3 independent experiments. 
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4.3 Recruitment of Multiple Signaling Pathways in Leachianone 
A-induced Apoptosis 
As far as apoptosis was confirmed, w e then aimed to work out the underlying 
mechanisms responsible for this Leachianone A-induced cell death in HepG2 
and RHepG2 cells. 
Apoptotic cell death is triggered by intra-cellular cues, such as D N A d a m a g e 
and osmotic stress; as well as extra-cellular cues, like growth factor 
withdrawal, matrix attachment and direct cytokine-mediated killing, etc 
(Sellers ef al” 1999). Two central pathways are identified; one is the extrinsic 
(death receptor-mediated) pathway and a second, intrinsic (mitochondrial) 
pathway (Medema ef al., 1997, Green et al., 1998). These two pathways 
converge and connect to each other on the caspase cascade. 
4.3.1 Activation of Caspases-3, -8, and -9 
The core apoptotic machinery comprises the cysteine-aspartic acid 
proteases (caspases), members of B-cell lymphoma 2 (Bcl-2) family and 
apoptosis protease-activating factor-1 (Apaf-1). Caspases are cysteine 
proteases, which cleave proteins at aspartic acid residues accommodated 
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within a tetra-peptide recognition motif. Usually, they are classified into 
initiator caspases (caspases-1, -2, -4, -8, -9, -10 and -14) and effector caspases 
(caspase-3, -6 and-7) (Muzio ef al., 1998, Srinivasula ef al., 1998). Proteolytic 
cleavage of a set of vital substrates by effector caspases largely determines 
the features of apoptotic cell death (Zimmermann ef al., 2001). 
Caspase-3, one of the chief effector caspases, plays an indispensable role in 
the execution of morphological and biochemical changes in apoptosis. In 
this connection, the level of procaspase-3 in cells before and after 
Leachianone A application was first examined. As reflected from the results, 
cleavage of the precursor of caspase-3 happened following the treatment of 
Leachianone A in a dose-dependent manner (Fig. 4.3.1.1 A). Concurrently, 
a drop in the protein level of the pro-form of both its upstream initiator 
caspases, caspases-8 and -9, was also seen in the study (Fig. 4.3.1.IB & 
4.3.1.IC). These implied that both of the extrinsic and intrinsic pathways 
were likely to participate in the activation of caspase-3. 
With caspase-3 enzyme activated, the follow-up experiment was to explore if 
there were proteolytic cleavages of its specific downstream substrates, such 
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as inhibitor of caspase-activated DNase (ICAD) and poly-(ADP-ribose) 
polymerase (PARP). ICAD is involved to repress the DNase, which otherwise 
brings about large scale DNA fragmentation (Enari ef a/., 1998). PARP, on 
the other hand, aids in protecting the DNA or repairing the damaged DNA 
(Soldani ef al., 2002). When both ICAD and PARP are cleaved, an apoptotic 
DNA fragmentation means to start. In our study, data from the Western blot 
analysis clearly illustrated that degradations of ICAD and PARP appeared in a 
fashion coinciding with the caspase-3 activation (Fig. 4.2.1.IE & 4.3.1.IF). 
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Fig. 4.3.1.1 Activation of caspases-3, 8 and 9 as well as induction of ICAD and 
PARP cleavages by Leachianone A in HepG2 and RHepG2 cells. 
Cells (1 X 106) were incubated with vehicle only (lanes 1 & 5) and Leachianone A at 
concentrations of 10 i^g/ml (lanes 2 & 6), 20 |ig/ml (lanes 3 & 7) and 30 iig/ml (lanes 4 
& 8) for 48 hours at 37°C, 5%�C〇2.� (A)�Probed�with�anti-procaspase-3�(35�kDa)�
antibody.� (B)�Probed�with�anti-procaspase-8�(55�kDa)�antibody.� (C)�Probed�with�
anti-procaspase-9� (46�kDa)�antibody.� (D)�Probed�with�anti-beta-actin� (42�kDa)�
antibody�as�loading�control. (E) Probed with anti-ICAD (45 kDa) antibody. (F & G) 
Probed with anti-PARP (116 kDa as intact form and 85kDa as cleaved form) antibody. 
(H) Probed with anti-beta-actin (42 kDa) antibody as loading control. Data are from 
a representative of 4 separate experiments. 
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To further verify the existence of a functionally active caspase-3 in cells, 
another test was performed in parallel to determine the caspase-3 enzymatic 
activity. In the course of apoptosis, the activated caspase-3 is recognized 
and labeled with carboxyfluorescein (FAM)-labeled peptide fluoromethyl 
ketone (FMK) caspase inhibitors (FAM-peptide-FMK). The peptide sequence 
aspartate-glutannate-valine-glutamate (DEVD) used in the experiment is 
specially designed for its tight binding with the activated caspase-3, so that 
the cells with enhanced fluorescence signals are readily figured out. 
Concordant with our findings in the Western blot study (Fig. 4.3.1.1), cells 
incubated with elevated concentrations of Leachianone A displayed a 
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Fig. 4.3.1.2 Study of the enhancement of caspase-3 activity in Leachianone 
A-treated HepG2 cells. 
H e p G 2 cells (1 x 106) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 ^ ig/ml (B), 20 [ig/ml (C) and 30 |ag/ml (D) for 48 hours at Z K . 5% 
C〇2.� Cells�with�activated�caspase-3�bound�to�the�FAM-peptide-FMK�inhibitor�were�
detected�using�flow�cytometry.� Marker�Ml� corresponded�to�the�cell�fraction�with�
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Fig. 4.2.1.3 Study of the enhancement of caspase-3 activity in Leachianone 
A-treated RHepG2 cells. 
R H e p G 2 cells (1 x 106) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 iig/ml (B), 20 i^g/ml (C) and 30 ^ g/ml (D) for 48 hours at 37oC, 5% 
C〇2.� Cells�with�activated�caspase-3�bound�to�the�FAM-peptide-FMK�inhibitor�were�
detected�using�flow�cytometry.� Marker�Ml�corresponded�to�the�cell�fraction�with�




^ , Results and Discussion 
4.3.2 Altered Expressions of Bcl-2 Family Proteins 
Apart from caspases, Bcl-2 family proteins are the essential players to 
promote or intervene the apoptotic process as well (Jurgensmeier ef aL, 
1998). Bcl-2 family is chiefly consisted of pro-apoptotic factors, like Bad, Bak, 
Box, Bd-Xs, Bik, Bim, Bok, Krk and Mtd; as well as anti-apoptotic factors: Al, 
Bcl-2, BC I -XL , B C I - W and Mcl-l (Wang ef al., 2001). In response to different 
signals, these proteins interact with each other to form homo-dimers or 
hetero-dimers, which finally decide the fate of the cells. 
Accordingly, the protein expression patterns of certain Bcl-2 family members 
were evaluated. Results revealed that the expression level of the 
pro-apoptotic protein. Bid, steadily dwindled as the dosage of Leachianone 
A raised (Fig. 4.3.2.1 A). This was attributed to the processing of Bid into a 
truncated form, tBid. Down-regulations of anti-apoptotic proteins, for 
instance Bcl-2 and Bcl-Xu along with an up-regulation of the pro-apoptotic 
protein, Bad, were also detected in this apoptotic incident (Fig. 4.3.2.IC, 
4.3.2.1 D, 4.3.2.1 F). Notwithstanding, the protein expression of Box remained 
almost unchanged (Fig. 4.3.2.1 G). Taken together, the net effect herein was 
to propagate the downstream caspase cascade; and dispose the cells to 
112 
Chapter 5 




Results and Discussion 
1 2 3 4 5 6 7 8 
HepG2 RHepG2 
！拜丨丨…,丨I f ' 、 ^ ^ 麵 , ‘ 讀� A)�Bid�(22kDa)�
画麵蘭「」___III II11謂iiiiiiii.....…..iM鯽__「| I……jrn. Tiiii—rir� 」_,aiii»»1 …beta-actin (42kDa) 
I 一 ，� I� C)�Bcl-2�(25kDa)�
二 “ � l l ^ ^ W l� D , —�
娜 _ _ I i i i i i� ii_IMillII_I 而 . .—__•_「.T彳nf»iiigiiip»iwi|j|^ 『. _I .... j E) beta-actin (42kDa) 
^mrnmm I 一� F)�Bad�(25kDa)�
‘ 臺 ^ • 丄 , ‘ ..‘.，， lifiiitffi". lifiiMifrr 
1 II l _ l l _ JIII 1 1 1 — G) Bax(23kDa) 
'^^mm^ 一 - 丨 " I I _ — _ ) 
Fig. 4.3.2.1 Alteration of Expression Levels of Bcl-2 family proteins by 
Leachianone A in HepG2 and RHepG2 cells. 
Cells (1 X 106) were incubated with vehicle only (lanes 1 & 5) and Leachianone A at 
concentrations of 10 ng/ml (lanes 2 & 6), 20 i^g/ml (lanes 3 & 7) and 30 ing/ml (lanes 4 
& 8) for 48 hours at 37°C, 5% C O 2 . (A) Probed with anti-bid (22 kDa) antibody. (B) 
Probed with anti-beta-actin (42 kDa) antibody as loading control. (C) Probed with 
anti-bcl-2 (25 kDa) antibody. (D) Probed with anti-bcl-Xi (28 kDa) antibody. (E) 
Probed with anti-beta-actin (42 kDa) antibody as loading control. (F) Probed with 
anti-bad (25 kDa) antibody. (G) Probed with anti-bax (23 kDa) antibody. (H) 
Probed with anti-beta-actin (42 kDa) antibody as loading control. Data are from a 
representative of 3 separate experiments. 
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4.3.3 Loss of Mitochondrial Membrane Potential 
So far, there are several death signaling pathways reported, including the 
extrinsic (death receptor-mediated) pathway; and the intrinsic 
(mitochondrial) pathway. They act in diverse routes; and recruit different 
molecules to move forward. Yet, they are capable of influencing each 
other through the Bcl-2 family member, known as Bid. Briefly, caspase-8 
cleaves the Bid to produce truncated Bid, which in turn, in co-operation with 
Bad, facilitates the release of cyt c from mitochondria, thereby causing the 
caspase adaptor protein Apaf-1 to activate caspase-9. Such kind of 
inter-connection allows amplification of signals in cells (Kaufmann et al., 
2000). 
Over the decades, accumulated evidence showed that mitochondria were 
pivotal in controlling cell life (Grutter et al., 2000). Early initiation of apoptosis 
is accompanied by the disruption of the mitochondrial membrane integrity, 
leading to a rapid collapse in the electrochemical gradient (Ly ef al., 2003). 
This prompted us to study the effect of Leachianone A on the mitochondrial 
trans-membrane potential (AWm) using a mitochondria- specific cationic dye 
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JC-1. Provided a high A W m in normal cells, JC-1 predominantly 
accumulates as J-aggregates in the mitochondria, emitting a red 
fluorescence. With a declined A W m in apoptotic cells, however, JC-1 
switches to its monomelic form; and stains a green colour. 
From the flow cytometric analysis, a remarkable attenuation of A W m was 
resulted in cells challenged with Leachianone A; whereas that in untreated 
cells was well maintained. In fact, presence of increasing concentrations of 
Leachianone A herein m a d e more and more cells susceptible to 
mitochondrial membrane depolarization (Fig. 4.3.3.1 & 4.3.3.2). 
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Fig. 4.3.3.1 Study of the loss of mitochondrial membrane potential in 
Leachianone A-treated HepG2 cells. 
H e p G 2 cells (3 x 10^) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 iig/ml (B), 20 i^g/ml (C) and 30 i^g/ml (D) for 48 hours at 37oC, 5% 
C〇2.� Cells�obtained�were�incubated�with JC-1 dye for staining. Flow cytometry 
was next used to measure the fluorescence emitted. Region R1 corresponded to 
the cell fraction with depolarized mitochondrial m e m b r a n e potential. Results are 
representative of 5 independent experiments. 
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Fig. 4.3.3.2 Study of the loss of mitochondrial membrane potential in 
Leachianone A-treated RHepG2 cells. 
R H e p G 2 cells (3 x 105) were exposed to vehicle only (A) and Leachianone A at 
concentrations of 10 ^ g/ml (B), 20 i^g/ml (C) and 30 ^ g/ml (D) for 48 hours at 2>7^C, 5 % 
C〇2.� Cells�obtained�were�incubated�with JC-1 dye for staining. Flow cytometry 
w a s next used to measure the fluorescence emitted. Region R1 corresponded to 
the cell fraction with depolarized mitochondrial m e m b r a n e potential. Results are 
representative of 5 independent experiments. 
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In line with the loss of A W m , efflux of some mitochondrial inter-membrane 
space proteins, like cyt c, apoptosis-inducing factor (AIF), Smac/ DIABLO, 
Omi/ HtrA2 and endonuclease G (endo G), is also regarded as a key 
regulatory procedure in the mitochondria-dependent apoptosis (Verhagen 
et a/., 2000). Once released into the cytosol, these apoptogenic proteins 
assisted to trigger off cellular catabolic destruction (Loeffler et a/., 2001). 
In light of this, the status of these proteins present in mitochondria and cytosol 
in each cell panel was checked. It was obvious that incubation of cells with 
Leachianone A caused a dose-dependent decrease in the mitochondrial 
cyt c and AIF amounts, with a concomitant increase in the corresponding 
cytosolic fraction (Fig. 4.3.3.3 A 一�4.3.3.3�D).�
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； ‘� y：' A) mitochondrial cytc (17kD 
…““T^r^"" ‘ . '“’. ,/、, 
— 一� jjiiiiiWf.� B)�cytosolic�cyt�c�(17kDa)�
一 . ’ _ i M ^ l ^ m m A c y t o s o l i c AIF(57kDa) 
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Fig. 4.3.3.3 Release of cytochrome c (cyt c) and apoptosis-inducing factor (AIF) 
from mitochondria to cytosol in Leachianone A-treated HepG2 and RHepG2 
cells. 
Cells (1 X 106) were incubated with vehicle only (lanes 1 & 5) and Leachianone A at 
concentrations of 10 ng/ml (lanes 2 & 6), 20 fig/ml (lanes 3 & 7) and 30 |Lig/ml (lanes 4 
& 8) for 48 hours at 37°C, 5%�C〇2.� (A,�B)�Probed�with�anti-cytochrome�c�(17�kDa)�
antibody.� (C,�D)�Probed�with�anti-AIF�(57�kDa)�antibody. (E) Probed with anti-GRP 
75 (75 kDa) antibody as loading control for mitochondrial fraction. (F) Probed with 
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4.4 in vivo Tumor Growth Inhibition in HepG2-bearing Nude Mice 
In order to appraise if Leachianone A also reserves the ability to suppress or 
inhibit tumor growth in vivo, o nude mice animal model subcutaneously 
inoculated with HepG2 cells was employed. Following one month of drug 
administration, the tumor size was significantly diminished by 17% - 54% in 
Leachianone A-treated groups of nude mice, when compared to those 
solely given the vehicle (Fig. 4.4.1). And, the size diminution was just inversely 
proportional to the dosage of Leachianone A injected, a trend being 
consistent with the in vitro bioassays. Moreover, the plasma activities of the 
enzymes specific for heart and liver, namely creatine kinase (CK), lactate 
dehydrogenase (LDH), alanine transaminase (ALT) and aspartate 
transaminase (AST), in those Leachianone A-treated mice remained at 
normal levels, suggesting that the use of this compound did not produce any 
apparent toxicity to the hosts (Fig. 4.4.2). A slight increment in the plasma 
total LDH activity obtained in control group was possibly an artifact due to 
the in vitro haemolysis during preparation; or otherwise an outcome of the 
spread of the solid tumor. In such an assumption, calculation of the activity 
of a certain isoform of the enzyme (that is, LDH-1/ 4H of higher relevance to 
the heart) was required, so as to have a more precise comment on the effect 
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Results and Discussion 
4.5 Conclusion 
As a whole, w e expounded that Leachianone A treatment was not coupled 
with any cell cycle arrest in hepatoma cells, HepG2 and RHepG2. Instead, it 
mediated the activation of apoptotic programme (through both extrinsic 
and intrinsic pathways) in cells, ascertained by the manifest changes in all the 
molecular markers analyzed (Fig. 4.1.2 & 4.1.3, 4.2.1.2 & 4.2.1.3, 4.2.2.1.1 & 
4.2.2.1.2, 4.2.2.2.1, 4.3.1.1 - 4.3.1.3, 4.3.2.1, 4.3.3.1 - 4.3.3.3, 4.4.1 & 4.4.2). 
In many aspects, the killing efficiency of Leachianone A in RHepG2 cells 
happened to preponderate over that in HepG2 cells. It was substantiated 
by the vaster population of cells found in the sub-Gl peak and in the annexin 
V-positive quadrants (inclusive of early and late apoptotic cells), advanced 
D N A fragmentation and presence of more cells containing active caspase-3 
enzyme, etc in RHepG2 cells in comparison to HepG2 cells, as the same 
concentration of Leachianone A was added. The figures from the in vitro 
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^ , Results and Discussion 
Up till now, the exact reasons for this peculiar phenomenon are not fully 
understood. W e speculate that it has something to do with the drug entry 
and targeting into and inside the cells. In recent publications, it was 
mentioned that P-glycoprotein (Pgp) over-expression in clinical cancers 
simply did not impede the cytotoxicity of flavonoids from Sophora flavescens, 
including Leachianone A (Maia ef al., 1998, Choi ef al” 1999). Besides, 
expanding evidence in support of the involvement of lysosome in apoptosis 
arised lately (Ferri et al；�2001,�Bivik et al., 2006,�Skommer ef al.,�2006).� It�is�
possible�that Leachianone A hastens the lysosomal rupture (LMP) to leak out 
the digestive enzymes in RHepG2 cells; and helps accelerate the process. 
Another ground to account for this situation lies on the altered property of 
mitochondria in RHepG2 cells. Perhaps, Leachianone A modulates the 
fluidity of biological membranes, which subsequently favors the response of 
mitochondrial permeability transition (MPT) (LIuis ef al., 2003, Colell et al., 
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CHAPTER 5 
RESULTS and DISCUSSION --
MECHANISTIC STUDY OF SOPHORAFLAVONE J-INDUCED CELL DEATH IN 
HEPATOMA CELLS HepG2 
5.1 Execution of Cellular Apoptosis 
In the last chapter, w e discussed about the assorted bioassays representative 
of apoptosis. Herein, w e followed a similar approach to solve out the effect 
of Sophoraflavone J on HepG2 cells. (Work on RHepG2 cells was sacrificed 
owing to the limited availability of Sophoraflavone 丄）It�was�discovered�that�
Sophoraflavone J did not stimulate cell cycle arrest in HepG2 cells (Fig. 5.1.1). 
But rather, it tipped off an apoptotic cell death, as manifested by PS 
translocation onto the cell membrane surface and inter-nucleosomal DNA 
degradation (Fig. 5.1.2 - 5.1.4). 
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Fig. 5.1.1 Cell cycle analysis of HepG2 cells treated with vehicle or 
Sophoraflavone J for 48 hours. 
Cells (3 X 105) were exposed to vehicle only (A) and Sophoraflavone J at 
concentrations of 5 ^ ig/ml (B), 10 i^g/ml (C), 15 ^ ig/ml (D) and 20 ^ g/ml (E) for 48 hours 
at 37°C, 5%� C〇2.� Cells�harvested�were� stained�with�PI�and� subjected�to�flow�





^ , Results and Discussion 
‘ ‘ ^ ^ 5.8% 
5.8% I Late apoptosis/ 
n necrosis 
89.7% •: • 4.1% : 
p. •  •• :•: PI 
••• ••• Normal Early 
' . c ^ ^ B ^ S cells apoptosis 
10° 10^  10^  1CP 10* 丨丨丨"“‘• 
• 89.7% Empty 4/1%画 d门nGXlPI V-FITC 
6.8% ^ ^ 7.7% 
0.4% ' ：‘^]^ 6.8% 专 0.3% "I 
‘85.9% ； 8 2 . 0 % • 
• “ “ •_ • • 
PI p . ；� p .� ^�
; ：身 
10° 101 102 103 10* 10° 10^  102 103 10* 
85.9% Empty 6.9% 82.0% Empty 9.9% 
^ j g t 23.0% 25.6% 
o 0.2% o 1 . 6 % ^ 
^ 10° 101 IQ2 103 10* " 10° io^  T^ 10* 
49.0% Empty 27.9% 47.1% Empty 25.8% 
annexin V-FITC 
Fig. 5.1.2 Annexin V-FTIC / PI staining of HepG2 cells treated with vehicle or 
Sophoraflavone J for 48 hours. 
Cells (3 X 105) were exposed to vehicle only (A) and Sophoraflavone J at 
concentrations of 5 |ig/ml (B), 10 ^ ig/ml (C), 15 |ig/ml (D) and 20 jig/ml (E) for 48 hours 
at 37°C, 5%�C〇2.� Cells�collected�were�passed�to�annexin V-FITC and PI staining, 
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Fig. 5.1.3 TUNEL assay of HepG2 cells treated with vehicle or Sophoraflavone J 
for 48 hours. 
Cells (1 X 106) were exposed to vehicle only (A) and Sophoraflavone J at 
concentrations of 5 ing/nnl (B), 10 |ig/ml (C), 15 i^g/ml (D) and 20 lug/ml (E) for 48 hours 
at 37°C, 5%�C〇2.� Numbers�of�cells�with�D N A� breaks�were�determined� by�flow�
cytometry.� Marker�Ml�corresponded�to�the�cell�fraction�with�D N A�breaks�labeled�
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Fig. 5.1.4 Induction of DNA fragmentation in Sophoraflavone J-treated HepG2 
cells. 
Cells (1 X 106) were incubated with vehicle only (lane 2) and Sophoraflavone J at 
concentrations of 5 |ig/ml (lane 3), 10 |ig/ml (lane 4), 15 ^ ig/ml (lane 5) and 20 ^ ig/ml 
(lane 6) for 48 hours at 37°C, 5%�C〇2.� D N A�laddering�pattern�was�observed�by 2% 
agarose gel electrophoresis. lOObp D N A marker (lane 1) was positioned aside for 
size indication. Results are representative of 4 independent experiments. 
137 
Chapter 5 
^ , Results and Discussion 
5.2 Involvement of Multiple Signaling Pathways in Sophoraflavone 
J-induced Apoptosis 
In the course of apoptosis, w e noticed that cleavages of pro-caspases-8 and 
-9 c a m e up in Sophoraflavone J-treated cells at concentrations of 15 jug/ml 
or higher (Fig. 5.2.1 B & 5.2.1C). Consequently, they brought about the 
proteolytic processing of caspase-3 zymogens into active enzymes (Fig. 
5.2.1 A). The activity of activated caspase-3 was seen with the cleavages of 
downstream substrates, ICAD and PARP, in Western blotting and the 
enhanced fluorescence signal in enzymatic activity assay (Fig. 5.2.1 E & 5.2.1 F, 
5.2.2). 
For the expression patterns of Bcl-2 protein family members, there was a 
dose-dependent lessening in the level of Bid upon exposure to 
Sophoraflavone J (Fig. 5.2.3 A). Meanwhile, under-expressions of 
anti-apoptotic proteins Bcl-2 and BCI-XL; together with over-expressions of 
pro-apoptotic proteins Bad and Box, were also attended (Fig. 5.2.3 C 一�5.2.3F).�
These�directed�the disorganization of mitochondrial membrane, thereby 
causing the dissipation of membrane potential (AWm) as well as the release 
of apoptogenic proteins, such as cyt c and AIF, from mitochondria into 
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cytosol (Fig. 5.2.4 & 5.2.5 A - 5.2.5D). 
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Fig. 5.2.1 Activation of caspases-3, 8 and 9 as well as induction of ICAD and 
PARP cleavages by Sophoraflavone J in HepG2 cells. 
Cells (1 X 106) were incubated with vehicle only (lane 1) and Sophoraflavone J at 
concentrations of 5 |ig/ml (lane 2), 10 |ig/ml (lane 3), 15 lug/ml (lane 4) and 20 iig/ml 
(lane 5) for 48 hours at 37°C, 5% CO2. (A) Probed with anti-procaspase-3 (35 kDa) 
antibody. (B) Probed with anti-procaspase-8 (55 kDa) antibody. (C) Probed with 
anti-procaspase-9 (46 kDa) antibody. (D) Probed with anti-beta-actin (42 kDa) 
antibody as loading control. (E) Probed with anti-ICAD (45 kDa) antibody. (F) 
Probed with anti-PARP (116 kDa as intact form and 85kDa as cleaved form) antibody. 
(G) Probed with anti-beta-actin (42 kDa) antibody as loading control. Data are 
from a representative of 3 separate experiments. 
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Fig. 5.2.2 Study of the enhancement of caspase-3 activity in Sophoraflavone 
J-treated HepG2 cells. 
HepG2 cells (1 x 106) were exposed to vehicle only (A) and Sophoraflavone J at 
concentrations of 10 jig/ml (B), 20 i^g/ml (C) and 30 lug/ml (D) for 48 hours at�37。C, 5% 
C〇2.� Cells�with�activated�caspase-3�bound�to�the�FAM-peptide-FMK�inhibitor�were�
detected�using�flow�cytometry.� Marker�Ml�corresponded�to�the�cell�fraction�with�
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Fig. 5.2.3 Alteration of Expression Levels of Bcl-2 family proteins by 
Sophoraflavone J in HepG2 cells. 
Cells (1 X 106) were incubated with vehicle only (lane 1) and Sophoraflavone J at 
concentrations of 5 |ig/ml (lane 2), 10 ^ ig/rnl (lane 3), 15 ng/ml (lane 4) and 20 lug/ml 
(lane 5) for 48 hours at 37°C, 5%�C〇2.� (A)�Probed�with�anti-bid�(22�kDa)�antibody.�
(B)�Probed�with�anti-beta-actin�(42�kDa)�antibody�as�loading�control.� (C)�Probed�
with�anti-bcl-2�(25�kDa)�antibody.� (D)�Probed�with anti-bcl-XL (28 kDa) antibody. (E) 
Probed with anti-beta-actin (42 kDa) antibody as loading control. (F) Probed with 
anti-bad (25 kDa) antibody. (G) Probed with anti-bax (23 kDa) antibody. (H) 
Probed with anti-beta-actin (42 kDa) antibody as loading control. Data are from a 
representative of 3 separate experiments. 
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Fig. 5.2.4 Study of the loss of mitochondrial membrane potential in 
Sophoraflavone J-treated HepG2 cells. 
H e p G 2 cells (3 x�1〇5)�were�exposed�to�vehicle�only�(A)�and�Sophoraflavone J at 
concentrations of 5 ^ g/ml (B), 10 i^g/ml (C), 15 jig/ml (D) and 20 ！ag/ml (E) for 48 hours 
at 37°C, 5%�C〇2.� Cells�obtained�were�incubated�with JC-1 dye for staining. Flow 
cytometry was next used to measure the fluorescence emitted. Region R2 
corresponded to the cell fraction with depolarized mitochondrial m e m b r a n e 
potential. Results are representative of 3 independent experiments. 
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Fig. 5.2.5 Release of cytochrome c (cyt c) and apoptosis-inducing factor (AIF) 
from mitochondria to cytosol in Sophoraflavone J-treated HepG2 cells. 
Cells (1 X 106) were incubated with vehicle only (lane 1) and Sophoraflavone J at 
concentrations of 5 jig/rril (lane 2), 10 lug/ml (lane 3), 15 |ig/ml (lane 4) and 20 iig/ml 
(lane 5) for 48 hours at Zl^C, 5 %�C〇2.� (A,�B)�Probed�with�anti-cytochrome�c�(17�kDa)�
antibody.� (C,�D)�Probed�with�anti-AIF�(57�kDa)�antibody. (E) Probed with anti-GRP 
75 (75 kDa) antibody as loading control for mitochondrial fraction. (F) Probed with 
anti-beta-actin (42 kDa) antibody as loading control for cytosolic fraction. Data are 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results and Discussion 
5.3 Differential Proteomes of Control and Sophoraflavone J-treated 
HepG2 Cells 
Today, advances in genomics and proteomics hold huge potentials for 
prognostic, diagnostic and therapeutic applications (Srinivas ef oL, 2001). 
Active genes, their corresponding protein products and other organic 
chemicals impart the molecular signposts of the biologic state of a cell at a 
specific circumstance. Thus, the global gene and protein expression studies 
are always of a great value in searching for the biomarkers important for early 
disease detection as well as identification (Chambers ef a/., 2000, Ryu ef a/., 
2003). 
Proteomics is one of the popular technologies recently emerged in the field 
of cancer research over genomics (Seow ef a/., 2000). It is believed that 
proteins are the functional outputs of expressed genes; and the proteomic 
method enables the differential display of the proteomic asset of normal and 
carcinoma cells in response to the genetic and environmental impacts, and 
establishes a direct means to delineate the exact role of genes (Pandey ef al., 
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2000). In principal, the proteomics is dominated by two techniques, the first 
being the array of complex samples by two-dimensional gel electrophoresis 
(2-DE); and the other, the computational interpretation of the proteins by 
matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS). In this project, w e m a d e use of the proteomics; and 
obtained the characteristic 2-DE maps of the whole lysates of control and 
Sophoraflavone J-treated (20 |ag/ml; 48 hours) HepG2 cells (Fig. 5.3.1). The 
dosage and time adopted were the ones conferring a marked change in 
cells challenged with Sophoraflavone J, as referred to the previous apoptotic 
study. In an overview, a total of 22 (14 up-regulated and 8 down-regulated) 
protein spots were annotated; their respective identities and reported 


















































































































































































































































































































































































































































































































Results and Discussion 
A control treated control treated 
^^^mrn^^m^mmm "^^^mmmmmmsm^'^ 'Mmfwwm^mmmmmmmmm wMW^mmmmwrnrmi^mm 
fciiiiiliifciiililliili ^^mm^rn^^^m 
丨。％• ： ： t巧（ 
a & b . M H C class II HLA-DQ-beta-1 c. hepatocellular carcinoma 
associated antigen 66 
d. heterogeneous nuclear e. far upstream element-binding 
ribonucleoprotein A2/ B1, isoform B1 protein, FUBI protein 
^mm^imi tg* ,1 
f. heat shock 27kDa protein 1 g. heat shock 70kDa protein 9B 
h. 78kDa glucose-regulated i. peroxiredoxin 1 
protein (GRP78; BiP) 




Results and Discussion 
A control freated control treated 
I 个‘ ^ m ^ m 
I. proteosome component C9 m . hepatoma-derived growth 
factor (HDGF) 
fe舞vf：. 
n 4 n _ 
X二.、'�.、:、、- IttM^^X 
n. keratin, type 11, 6A 
153 
Chapter 5 
Results and Discussion 
B 
control treated control treated 
O. Vimentin p. cofilin 1 
：,“'， “ , ...... fe — z fe^ ,f 
q. transgelin 2 r. enclose, alpha 
；乂、‘ 、赣 \ , , • 卜 ， r f 
, ‘“ ‘ ， I 孤 # 
S. translation elongation factor t. protein disulfide-isomerase 
eEF-1-alpha 
u. peptidylproyi isomerase A, isoform 1 v. prohibitin 
Fig. 5.3.2 Comparison of the protein expression profiles of control and 
Sophoraflavone J-treated HepG2 cell samples. 
Image analysis of the stained 2D-gels was performed using computer software 
(ImageMaster 2D Platinum; version 5.0). Spots with over-expressed (A) and 
under-expressed (B) levels were indicated by arrows. Their identities (a - v) were 
searched in SWISS-PROT and NCBI non-redundant databases, respectively. Results 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results and Discussion 
Out of these candidates, w e picked four - heat shock protein 70 (HSP70), 
glucose-regulated protein 78 (GRP78), transgelin 2 (TAGLN2) and alpha 
enclose (ENOl) - to have Western blotting for validation of their differential 
expressions, subsequent to 48-hour Sophoraflavone J incubation (Fig. 5.3.3). 
Besides, w e also conducted real-time PCR to examine whether the regulation 
lied at the transcriptional level or not. Interestingly, our findings pinpointed 
that m R N A and protein patterns were quite correlative with each other; an 
exception was HSP70 (Fig. 5.3.4 & Table 5.3). The discrepancy was possibly 
due to some other regulatory units in cells, which contributed to the 
increased translation of the existing m R N A and the decreased elimination of 
the encoded protein (Nordengren et al., 1998, Pradet-Balade et al., 2001). 
157 
Chapter 5 
Results and Discussion 
1� 2�
P U I 广 i� A)�heat�shock�protein�70�(70kDa)�
^^^^^^jljl^ l^llllljllllllllll^^^lllllllllllll^lllll^llllll^ � B)�beta-actin�(42kDa)�
C)�glucose-regulated�protein�78�(78kDa)�
D)�beta-actin�(42kDa)�
^ m m i l l l y g ^ ^ ^ ^ ^ ^ E) transgelin 2 (22kDa) 
F) b e f t i n (42kDa) 
G) alpha enolase (47kDa) 
iiii ��i[l��l��ll�l^llll�ll^illiiM^i^^mmil 
^^^lUllljlljjll^^j^jjjj^^^^^^j^� H)�beta-actin�(42kDa)�
Fig. 5.3.3 Confirmation of the altered expressed protein molecules in 
Sophoraflavone J-treated HepG2 cells by Western blotting. 
Cells (1 X 106) were incubated with vehicle only (lane 1) and Sophoraflavone J at a 
concentration of 20 |ig/ml (lane 2) for 48 hours at 37°C, 5%�C〇2.� (A)�Probed�with�
anti-HSP�70�(70�kDa)�antibody.� (C)�Probed�with�anti-GRP�78�(78�kDa)�antibody. (E) 
Probed with anti-TAGLN 2 (22 kDa) antibody. (G) Probed with anti-ENO 1 (47 kDa) 
antibody. (B, D, F & G) Probed with anti-beta-actin (42 kDa) antibody as loading 















































































































































































































































































































































































































































































Results and Discussion 
, _ ! t o i n i i ^ r i i 「 — a & j u s : ， 
control� treated� control� treated�
HSP70� —� increased� —� decreased�
GRP78� —� increased� —� increased�
TAGLN2 — decreased — decreased 
ENOl — decreased — decreased 
Table 5.3 A review of the mRNA and protein levels of the 4 candidates in control 
and Sophoraflavone J-treated HepG2 cells. 
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In encounter with Sophoraflavone J, lots of proteins in cells were switched up 
or down to make up the branching, complicated cellular response in return. 
These proteins are thought to be linked with a wide range of human tumors in 
many facets. However, there is no precise sequence for each protein 
coming between one and the other; they are instead inter-reliant and 
multi-directional. 
From literature review, HSP70 is an anti-apoptotic chaperon protein 
abundantly and preferentially expressed in human cancers (Kaureta/., 2000, 
Nylandsted ef a/., 2000). Neutralization of its function and/ or repression of its 
expression often ends up in a yet unknown caspase-independent death 
pathway, in which other anti-apoptotic proteins, like Bcl-2 and BCI-XL, etc 
failed to rescue the cells (Zhao ef al., 2005). More to this, inactivated HSP70 
results in a high rate of spontaneous chromosomal aberrations and genome 





Results and Discussion 
In our situation, HSP70 up-regulation was presumably a mechanism employed 
by the cells to counteract with the lethal stresses from driving them to die. In 
fact, acute production of HSP proteins was repeatedly found in patients 
following diverse forms of cancer treatments as a very short-termed response. 
On recovery, such proteins were continuously down-regulated to allow 
selective tumor cell death (Schueller ef al” 2004). Possibly, Sophoraflavone J 
got a time lag in depleting endogenous HSP70 to a minimal level yet to be 
observed post-48-hour application. 
GRP78 is another chaperon protein located at the endoplasmic reticulum (ER) 
lumen for nascent polypeptide folding and secretion (Rao et al” 2002). 
Unlike HSP70, GRP78 is unresponsive to heat stress; but is induced by glucose 
deprivation. ENOl is characterized as an evolutionarily conserved 
cytoplasmic enzyme involved in catalyzing the inter-conversion reaction of 
2-phosphoglycerate and phosphoenolpyruvate in glycolysis. There are 
three isoenzymes of enolase, namely alpha- (a-), beta- ((3-) and gamma- (y-) 
enolase. The former is detected in most tissues; whereas the latter two are 
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utterly in muscle and neural tissues, respectively (Piast et a/., 2005). Herein, 
up-regulation of GRP78 and down-regulation of ENOl revealed that the cells 
were short of energy source supply in the presence of Sophoraflavone J. 
TAGLN2 is a 22kDa monomeric protein containing nuclear factor-binding 
motifs to modulate transcription in cells (Camoretti-Mercado ef al., 1998). It 
is capable of gelling actin filaments rapidly; and affecting the expression of 
actin-associated proteins. Changed actin network was constantly 
accompanied by neoplasia and metastasis (Frances et al., 2006). So far, 
TAGLN2 over-expression is considered as a molecular signature for carcinoma 
cells (Chen ef al., 2005, Qi ef al., 2005). From our data, its down-regulation 
after the addition of Sophoraflavone J acted to help prevent the condition 
from deteriorating. 
Apart from Western blot experiment, w e included a functional study to 
explicate the strong expression of peroxiredoxin (Prx) proteins as well. It was 
postulated that Sophoraflavone J boosted up the generation of reactive 
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oxygen species (ROS) in cells, which subsequently enriched the ROS-sensitive 
Prx proteins for an antagonizing action. Usually, cellular ROS level was 
negatively associated with the glutathione (GSH) changes (Fujii et al., 2002). 
And, in our analysis, abated glutathione was described with a fall in the 
fluorescence signals, because of the poor formation of monochlorobimane 
(MCB)-glutathione adducts (Fig. 5.3.5). As such, w e knew that the 
up-regulation of Prx proteins was accredited to the escalated ROS level in 
Sophoraflavone J-treated cells. 
To conclude, the ultimate goal of this part was to find out the novel 
non-apoptotic cell-killing mechanism(s) allied to drug treatment. Down-
regulation of ENOl and TAGLN2 proteins herein inferred a nutrient/ energy 
dispossession and cytoskeleal reorganization within the cells by 
Sophoraflavone J. At the same moment, apoptosis-related molecules, 
including HSP70 and Prx 1 and 6 proteins, also shown to join in the process. 
HSP70 was versatile in annulling the apoptotic machinery either through 
binding with Box to stop its translocation to mitochondria; or through 
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interacting�with�Apaf-1�to�avert�the�formation�of�apoptosome.� Despite�this,�
HSP70�in�company�with�Prx�1�and�6�up-regulations�were�rather�a�fall-out�
feedback� from� the� intensive� R〇S� development.� Many� commercial�
anti-cancer�drugs�(e.g.�camptothecin� and� actinomycin� D)�engaged� to�
activate�the�mitochondrial�apoptotic�pathway�through�introduction�of�cells�


























































































































































































































































































































































































































Results and Discussion 
5.4 Conclusion 
As a whole, w e clarified that Sophoraflavone J elicited apoptosis in HepG2 
cells, dependent of both extrinsic and intrinsic pathways (Fig. 5.1.2 - 5.1.4, 
5.2.1 - 5.2.5). However, it demonstrated minute effect on cell cycle 
progression; the distribution of cells in the G1 or G 2 phases was more or less 
the same with or without drug treatment (Fig. 5.1.1). 
To further supplement the detailed mechanism behind the Sophoraflavone 
J-induced cell death, w e undertook a combined proteomic analysis; and 
spotted out manifold genuses of differentially expressed proteins (Fig. 5.3.1 & 
5.3.2). These proteins were classified into several categories based on their 
major biological roles, for instance membrane proteins/ antigens, structural 
proteins, transcriptional factors, glycolytic enzymes, heat-shock chaperon 
proteins (HSP), reactive oxygen species (ROS)-related proteins and 
proteosomes, etc (Table 5.2). From a set of preliminary tests, w e deduced 
that the cytotoxicity of Sophoraflavone J partially counted on its ability to 
incur nutrient deficiency and intra-cellular oxidation in HepG2 cells (Fig. 
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CHAPTER 6 
OVERALL CONCLUSION and FUTURE PERSPECTIVES 
Apoptotic Study 
The use of Chinese herbal ingredient(s) alone or in conjunction with some 
conventional drugs is a new trend in the contemporary clinical medicine to 
circumvent malignant cancers (Hemalswarya ef a/., 2006, Inane ef al., 2006, 
Xie ef al., 2006). In the present research, w e unraveled that both 
Leachianone A and Sophoraflavone J from Radix Sophorae were specific in 
their in vitro and in vivo cytotoxic activities against human hepatoma cells 
HepG2 and RHepG2; but not its normal liver cell counterpart WRL-68. 
Additionally, they were of extreme potency preceding the anti-cancer 
agents, cisplatin and taxol. 
Mechanistically, the two compounds worked to arrest cell proliferation and 
cause cell death through apoptosis, in which both the extrinsic (death 
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receptor-mediated) and intrinsic (mitochondrial) pathways were undergone. 
The proposed m o d e of action was that 1) Leachianone A or Sophoraflavone 
J interacted with the cognate receptors and initiated receptor trimerization; 2) 
trimerized receptors either recruited caspase-8 directly or in aid with some 
adaptor molecules; 3) activated caspase-8 then cleaved Bid into tBid; 4) tBid 
migrated to mitochondria and rendered the efflux of cyt c and AIF to cytosol; 
5) Apaf-1, cyt c and pro-caspase-9 next joined up for apoptosome, which 
gave rise to activated caspases-9 and -3 sequentially; 6) active caspase-3 
enzyme lastly mediated ICAD and PARP processing for DNA fragmentation as 
well as other morphological and biochemical changes during apoptosis. 
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Proteomic Study 
Proteomics possesses the advantage of viewing all the protein species within 
a single cell or tissue simultaneously (Towbin et a/., 2003). In practical, this 
methodology was most appreciated in biological science to, for example, 
elucidate protein changes between healthy and diseased subjects as well as 
during disease staging (Colantonio ef al., 2005). 
In the section of proteomics, w e hunted out a total of 22 protein spots 
expressed differentially in control and Sophoraflavone J-treated HepG2 cells. 
These proteins managed miscellaneous tasks, as grouped into: 1) membrane 
proteins/ antigens (MHC class II HLA-DQ-beta-1, HCC-associated antigen 66), 2) 
structural proteins (vimentin, cofilin 1, TAGLN2), 3) transcriptional factors 
(translation elongation factor eEF-1-alpha, hn RNP A2/ B1 isoform B1, FUBI protein), 4) 
glycolytic enzymes (ENOl), 5) heat-shock chaperon proteins (HSP) (HSP27, 
HSP70, GRP78), 6) reactive oxygen species (ROS)-related proteins (Prxl, Prx6] 
and 7) proteosomes (proteosome activator 28 alpha subunit, proteosome 
component C9), etc (hepatoma-derived growth factor, keratin type II 6A, protein 
disulfide-isomerase, peptidylproyi isomerase A isoform 1, prohibitin). According to 
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the experimental findings, w e surmised that Sophoraflavone J treatment 
directly or indirectly imposed on the cancer cells difficulties in consuming 
food sources and coping with oxygen species, before straightly getting to 
induce apoptosis. 
In the near future, effort will be extended to the characterization of the 
identified proteins so as to gain more insights in the comprehensive action 
mechanism of Sophoraflavone J in HepG2 cells. For instance, immuno-
staining will be manipulated to highlight the intra-cellular localization(s) of the 
candidate protein(s); and RNA interference (RNAi) will also be utilized to 
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